Abstract: Matrix metalloproteinases (MMPs) have traditionally been considered as tumor promoting enzymes as they degrade extracellular matrix components, thus increasing the invasion of cancer cells. It has become evident, however, that MMPs can also cleave and alter the function of various non-matrix bioactive molecules, leading to both tumor promoting and suppressive effects. We applied systematic review guidelines to study MMP8 in cancer including the use of MMP8 as a prognostic factor or as a target/anti-target in cancer treatment, and its molecular mechanisms. A total of 171 articles met the inclusion criteria. The collective evidence reveals that in breast, skin and oral tongue cancer, MMP8 inhibits cancer cell invasion and proliferation, and protects patients from metastasis via cleavage of non-structural substrates. Conversely, in liver and gastric cancers, high levels of MMP8 worsen the prognosis. Expression and genetic alterations of MMP8 can be used as a prognostic factor by examination of the tumor and serum/plasma. We conclude, that MMP8 has differing effects on cancers depending on their tissue of origin. The use of MMP8 as a prognostic factor alone, or with other factors, seems to have potential. The molecular mechanisms of MMP8 in cancer further emphasize its role as an important regulator of bioactive molecules.

Keywords: matrix metalloproteinase 8; cancer; prognosis; molecular mechanism; cancer drug therapy; systematic review

1. Introduction

The number of new cancer cases is expected to grow in the future as the lifetime risk of developing cancer rises with increasing aging of the population [1]. Survival has increased in many cancers [2] due to improvements in prevention [3], detection [4], diagnosis and treatment [5]. These advances have been facilitated by extensive basic and clinical research utilizing in vitro methods, genetic analysis and cell culture methods, as well as in vivo animal studies and clinical trials. Moreover, the identification of an increasing number of cancer biomarkers has improved cancer diagnostics and care [6]. Biomarkers, such as DNA, RNA, proteins, peptides or chemical modifications of biomolecules, are used to assess the risk of developing a specific cancer, and to measure treatment responses and
cancer progression [7]. Historically, biomarkers have been explored in blood, urine and tumors using immunoassays and immunohistochemistry.

Members of the matrix metalloproteinase (MMP) family of zinc-dependent proteinases have been proposed as biomarkers and therapeutic targets for various cancers [8]. These proteinases have been mostly considered tumor-promoting because of their indisputable role in one of the hallmarks of cancer progression—the degradation of the extracellular matrix (ECM) that correlates with cancer cell invasion and metastasis [9]. MMP8, also known as neutrophil collagenase or collagenase-2, cleaves triple helical type I collagen and numerous other ECM and non-ECM substrates [10]. MMP8 is released from polymorphonuclear neutrophils (PMN) and hence plays an important part in mediating inflammation. For example, expression of MMP8 is increased in gingivitis as well as periodontitis [11] and MMP8 has been shown to suppress neuroinflammation [12] and inflammation in osteoarthritis [13]. Although mostly released from neutrophils, MMP8 is also expressed by various other cells [14]. However, the functions of MMP8 seem to be highly diverse, and thus, no clear consensus for its role in cancer has been reached. Moreover, its molecular mechanisms in different cancer types are still largely unknown.

The previous review articles on the role of MMP8 in cancer are outdated, do not focus solely on MMP8 and are not systematic reviews on the subject [15,16]. By applying systematic review guidelines and methods, we gathered the original research articles published on MMP8 related to cancer and provide a comprehensive compilation of the current knowledge on the subject. We aim to create an overview of the potential prognostic value of MMP8 in blood and tumor samples as well as highlight the effect of genetic changes in MMP8 for prognosis. In vitro and in vivo (murine) studies are reviewed to emphasize the molecular mechanisms of MMP8 and finally, the use of MMP8 in all levels of cancer therapy is discussed.

2. Results

2.1. The Potential Use of MMP8 for Evaluating Cancer Prognosis

Prognosis refers to the likely course, duration and outcome of a disease based on its characteristics, such as tumor size in cancer. The statistically calculated terms of overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS) are often used to describe the prognosis of a patient. The Dictionary of the National Cancer Institute defines these terms as the average time from the start of treatment to when the patient is still alive (OS), or the time from the end of treatment for which the patient survives without any signs or symptoms of that cancer (DFS, sometimes referred as recurrence-or relapse-free survival, RFS). Prognostic biomarkers are biomolecules, such as DNA or protein, which inform the clinician of the patient’s status or enable them to predict the patient’s prospects, e.g., chance of recurrence [7]. Here we evaluated the measurement of MMP8 (gene expression and protein levels) in tumors and circulation, as well as genetic polymorphisms, as a prognostic marker.

2.1.1. Analysis of Tumoral MMP8 on Protein and mRNA Level

Levels of different molecules have been traditionally studied by visualizing target antigens using immunohistochemical methods on fresh frozen or formalin-fixed, paraffin-embedded (FFPE) tumor samples [17]. Tumor lysates can also be used as a source of protein for analysis [18]. Sometimes the tumor samples are collected as microarrays (tumor microarray, TMA) [19]. Tumoral mRNA expression has been usually studied by reverse transcriptase-polymerase chain reaction (RT-PCR) using RNA extracted from fresh or FFPE tumor tissue [20]. Yet mRNA can also be visualized in tumor sections by other methods such as in situ hybridization [21]. The studies on tumoral MMP8, both mRNA and protein, are collected in Table 1.
Table 1. Tumoral matrix metalloproteinase 8 expression and prognosis.

| Cancer         | Focus            | Method          | Study Size (Patients + Healthy Controls) | Expression and Prognosis (p-Value)                                                                 | Authors                                |
|---------------|------------------|-----------------|-----------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------------|
| Bladder       | mRNA RT-PCR      | 113 + 20        | Positively correlates with tumor grade (p < 0.001). | Wallard et al. 2006 [22]                                                                         |
| Bone          | Protein IHC      | 25 + 0          | 5/10 resection samples and 11/22 biopsies but 0/3 metastases show MMP8 staining. | Korpi et al. 2011 [23]                                                                           |
| Bone          | mRNA RT-PCR      | 29 + 0          | 5/29 chondrosarcoma tumors show expression. | Scully et al. 1999 [24]                                                                           |
| Breast        | mRNA RT-PCR      | 39 + 16         | Trend to positive correlation with tumor grade (ns). | Benson et al. 2013 [25]                                                                           |
| Breast        | Protein, mRNA RT-PCR, WB, IHC | 20 + 5 | No difference in mRNA. Protein correlates with stage (p ≤ 0.05). mRNA expression negatively correlates with LN involvement (p = 0.006). Better survival of patients without adjuvant therapy (p = 0.009). | Körhmann et al. 2009 [26]                                                                   |
| Protein, mRNA | IHC, RT-PCR      | 280 IHC, 250 RT-PCR + 10 |                                                                 | Gutierrez-Fernandez et al. 2008 [27]                                                            |
| Luminal A; mRNA | RT-PCR         | 295 + 0         | No correlation to clinicopathological features. | McGowan & Duffy 2008 [28]                                                                         |
| Luminal A; mRNA | ELISA           | 55 + 0          | No correlation to tumor size or LN metastasis. | Duffy et al. 1995 [30]                                                                           |
| Colorectal    | Protein IHC      | 548 + 0         | Very little staining (0.1-5%) in cancer cells. | Väyrynen et al. 2012 [32]                                                                       |
| Colorectal    | Protein ELISA    | 100 + 0         | Correlation with malignancy (p = NR). | Verspaget et al. 1999 [33]                                                                         |
| Colorectal    | Protein IHC      | 121 + 0         | No expression in cancer cells. Negative staining associates with stage I cancer (p = 0.022), T1 tumor (p = 0.005), diffuse type (p < 0.001), no LN metastasis (p = 0.016) and age under 67 (p = 0.007). Better prognosis for women with negative staining (p = 0.026). | Takehida et al. 1997 [34]                                                                   |
| Gastric       | Protein IHC      | 276 + 0         | No correlation to clinicopathological features. | Lin et al. 2017 [36]                                                                            |
| Gastric       | mRNA RT-PCR      | 34 + 34         | Lower mRNA expression in cancer tissue compared to paired healthy tissue. | de la Pena et al. 2014 [37]                                                                     |
| Gastric       | mRNA RT-PCR      | 17 + 22         | No correlation to tumor size or LN metastasis. | de la Pena et al. 2014 [37]                                                                     |
| Gastric       | Protein ELISA    | 81 + 0          | Expression higher (p ≤ 0.001) esp. in well-differentiated (p ≤ 0.002) tumors. No correlation to survival. High VEGF-C (p = 0.001) and low MMP8 level (p = 0.01) correlate with shorter CSS, combined VEGF-C+/MMP8- status correlate with poor CSS (p < 0.001). | Kubben et al. 2006 [38]                                                                         |
| Head and neck | OTSCC; protein IHC | 57 + 0          | No correlation to clinicopathological features or overall survival. | Åström et al. 2017 [39]                                                                         |
| Head and neck | OSCC, CSCC; protein IHC | 36 OSCC, 25 CSCC + 0 | No correlation to clinicopathological variables. | Ahmed Haji Omar et al. 2015 [40]                                                                 |
| Head and neck | OSCC; protein IHC | 25 + 0          | 5/25 tumors showed moderate levels. | Lawal et al. 2015 [41]                                                                           |
| Head and neck | OTSCC; protein IHC | 70 + 0          | No correlation to clinicopathological features. | Mäkinen et al. 2012 [42]                                                                         |
| Head and neck | Larynx; protein AG array | 7 + 5        | Levels higher compared to normal mucosa (p = NR). | Korampalli et al. 2011 [43]                                                                      |
| Head and neck | OTSCC; protein IHC | 90 + 0          | Correlation to better prognosis and lower-case fatality (p < 0.05). | Korpi et al. 2008 [44]                                                                           |
| Head and neck | SL, SCC; protein; mRNA | 32 + 32        | <20% tumors showed expression (mRNA/protein). | Xie et al. 2004 [45]                                                                            |
| Head and neck | SG; protein EIA   | 23 + 23         | No differences to normal tissue. | Kayano et al. 2004 [46]                                                                         |
| Head and neck | SCC; protein, mRNA | 19 + 0          | Low mRNA expression and protein levels in all samples. | Moilanen et al. 2002 [47]                                                                       |
| Cancer       | Focus     | Method          | Study Size (Patients + Healthy Controls) | Expression and Prognosis (p-Value)                                                                 | Authors                  |
|-------------|-----------|-----------------|------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------|
| Liver       | Protein   | IHC             | 73 + 0                                   | Co-overexpression with TGF-β1 predicts poor prognosis in HCC patients (p < 0.025). Correlation to cancer stage (p = 0.038) and metastasis (p = 0.049). | Qin et al. 2016 [48]    |
| Lung        | Protein   | FACS            | 22 SCC, 19 AC + 0                        | Higher in tumor (p = 0.0084) and SCC vs AC (p = 0.0022). Trend towards positive correlation with recurrence (ns). | Shah et al. 2010 [49]   |
| Ovarian     | Protein   | IHC             | 302 + 0                                  | Correlation to tumor stage (p ≤ 0.01), grade (p ≤ 0.01) and poor prognosis (p = 0.019).            | Stadlmann et al. 2003 [50]|
| Pancreas    | Protein   | LC-MS           | 9 SS, 10 LS + 0                          | High MMP8 levels in ovarian cyst fluid are associated with malignancy (p = NR).                    | Stenman et al. 2003 [51]|
| Skin        | nBCC; protein, mRNA | RT-PCR, WB | 22 + 22                                  | Higher levels in nBCC tumors (p < 0.0001), but no differences in mRNA expression.                | Ciampitska et al. 2018 [54] |
|             | SCC; protein | IHC             | 31 KA, 15 SCC + 0                        | More frequent levels in keratoacanthomas compared to SCCs (ns)                                  | Kuivinen et al. 2006 [55]|
|             | SCC; protein | IHC             | 9 SCC, 31 leg ulcers + 0                | Cannot distinguish between non-malignant leg ulcers and SCC.                                      | Impola et al. 2005 [56]  |
|             | Melanoma; protein | IHC             | 10 + 0                                  | Correlates with invasiveness (p = NR).                                                          | Gambiniardi et al. 2001 [57] |
|             | BCC; protein | IHC             | 54 + 16                                 | No correlation to collagenolytic activity.                                                       | Varani et al. 2000 [58]  |
| Soft tissue | Protein   | ICC             | 39 + 0                                  | 6/39 tumors have MMP8 staining.                                                                 | Roebuck et al. 2005 [59] |
| Thyroid     | mRNA      | cDNA array      | 131 + 0                                 | Higher expression in malignant neoplasms compared to benign.                                      | Kebebew et al. 2005 [60]|
| Uterine     | Protein   | EIA, IHC        | 53 + 30                                 | Higher expression (p < 0.05) in patients. No correlation to clinicopathological features.         | Ueno et al. 1999 [61]   |

Abbreviations: AC: Adenocarcinoma; AG array: Angiogenesis array; BCC: Basal cell carcinoma; CSCC: Cutaneous squamous cell carcinoma; CSS: Cancer specific survival; EIA: Enzyme immunoassay; ELISA: Enzyme-linked immunosorbent assay; FACS: Fluorescence activated cell sorting/flow cytometry; HCC: Hepatocellular carcinoma; ICC: Immunocytochemistry; IHC: Immunohistochemistry; ISH: In situ hybridization; LC-MS: Liquid chromatography—mass spectrometry; KA: Keratoacanthoma; LN: Lymph node; LS: Long survival; NR: Not reported; nBCC: Nodular basal cell carcinoma; ns: Not significant; OSCC: Oral squamous cell carcinoma; OTSCC: Oral tongue squamous cell carcinoma; RT-PCR: Real-time or reverse transcription polymerase chain reaction; SCC: Squamous cell carcinoma; SG: Salivary gland; SL: Supraglottic larynx; SS: Short survival; TGF-β1: Transforming growth factor β1; T1 tumor: Tumor extending to mucosal and submucosal layers according to tumor, node, metastasis (TNM) staging for gastric cancer; VEGF-C: vascular endothelial growth factor C; WB: Western blot.
2.1.1.1. No Clear Evidence for the Use of MMP8 Protein as a Prognostic Factor in Breast Cancer

MMP8 has been widely studied in breast tumors. Many studies have found no correlation between tumoral MMP8 expression and clinicopathological parameters [25,28,29]. Köhrmann et al. [26] detected a correlation between tumor grade and MMP8 protein levels, yet Sarper et al. [62] noticed a loss of MMP8 in myoepithelial cells during carcinogenesis. Gutierrez-Fernandez et al. [27] showed that MMP8 gene expression negatively correlated with lymph node involvement, but so far no other study has confirmed the correlation. Another study on breast cancer showed an association between MMP8 levels and the levels of metalloproteinase inhibitor 1 (TIMP-1) and MMP9 but not with tissue plasminogen activator, urokinase or their inhibitor (PAI-1) [30,63].

2.1.1.2. The Prognostic Value of Tumoral MMP8 Protein Levels in Skin Cancer Depends on the Subtype

A higher level of MMP8 in the epidermal-dermal border correlates with melanoma invasiveness [57]. However, in basal cell carcinoma, MMP8 protein was only detected in the dermis and no correlation to collagenolytic activity was observed [58]. Similarly, in squamous cell carcinoma (SCC) of the skin, the epithelial level of MMP8 was not useful in distinguishing chronic, non-malignant leg ulcers from SCC [56], nor to explain the aggressiveness of SCC in organ transplant recipients [64]. However, MMP8 was slightly more frequently detected in neutrophils in keratoacanthomas (~44%) compared to SCCs (~33%) [55].

2.1.1.3. Tumoral MMP8 Protein Level is an Applicable Biomarker Only in Tongue SCC among All Head and Neck SCCs

Analysis of MMP8, performed in a variety of different head and neck SCCs (HNSCCs), localized MMP8 protein to tumor cell islands, PMNs, plasma cells and fibroblasts [47]. MMP8 is abundant in oral squamous cell carcinoma (OSCC) tumors, but the higher level does not correlate with clinicopathological features nor does it increase the survival of the patients [40,41]. Additionally, MMP8 was shown to be present in the OSCC tumor interstitial fluid in samples collected during surgery and analyzed by mass spectrometry [65]. Yet in the SCC of oral (mobile) tongue (OTSCC), higher MMP8 in tumor favored better prognosis and lower mortality [44] although very high and negative levels hinted towards shorter DFS [42]. Furthermore, high vascular endothelial growth factor C (VEGF-C) together with low MMP8 levels in OTSCC tumors predicted worse prognosis even better than either of these factors separately [39]. Patients with tonsillar SCC showed higher MMP8 levels compared to patients with benign tonsillar disease [66]. MMP8 protein did not have a prognostic value in larynx tumors [43] where its levels varied greatly between patients, nor in supraglottic laryngeal tumors [45] where it was detected in only a few cells. Likewise, no difference in MMP8 protein levels were found between salivary gland carcinomas and normal tissue [46].

2.1.1.4. Tumoral MMP8 Protein Level Associated with Malignancy in Ovarian and Liver Cancer and Variates in Colorectal and Gastric Cancer

Qin et al. [48] found that MMP8 levels positively correlated with transforming growth factor β1 (TGF-β1) levels in hepatocellular carcinoma samples and their reciprocal increase was correlated with cancer stage, metastasis and shorter time-to-recurrence. High cytoplasmic levels of MMP8 in ovarian cancer cells correlated to tumor stage and overall poor prognosis, although not strongly enough to be useful as a prognostic marker [50]. In the fluid of ovarian cysts, elevated levels of MMP8 was associated with tumor malignancy [51]. It can be concluded, that high MMP8 seems to have a tumor-predicting role in both liver and ovarian cancers. In colorectal cancer, correlation between the step-wise increase of MMP8 levels and tumor malignancy was found [33]. Yet, others [31,34] did not find such a correlation and Väyrynen et al. found the MMP8 protein mostly in necrotic areas and neutrophils [32]. Similarly for gastric cancer, MMP8 level was higher in well-differentiated tumors, yet it did not affect patient survival [38]. In contrast, Laitinen et al. [35] found that negative MMP8 staining was associated with stage I cancer, T1 tumor stage as well as no lymph node metastasis and furthermore, women with negative MMP8 staining had a better prognosis.
For the following cancers, only single studies on the role of MMP8 exist. In the case of lung cancers, MMP8 level, and possibly also its effect, depend on the cancer subtype [49]. Pancreatic adenocarcinomas showed higher MMP8 levels compared to normal tissue [53], especially in patients with short survival time [52]. In uterine cancer, MMP8 was more abundant in tumor samples compared to normal tissue, but its level was not linked to any clinicopathological features such as tumor grade [61]. In chondrosarcoma [24] and soft tissue neoplasms [59], MMP8 staining was either absent or weak, and thus, no conclusions could be made of its role. In jaw cysts, MMP8 was only detected in plasma cells [67], and in osteosarcoma it was detected in about 50% of biopsy and resection samples but not at all in metastases [23].

2.1.1.5. MMP8 mRNA Expression is Rarely Detected in Patient Samples

The expression of MMP8 mRNA has been detected only in a few chondrosarcomas [24], hepatocellular carcinoma [68] and gastric cancer samples [37]. In bladder tumors, MMP8 mRNA expression was not strong enough to show significant correlation to malignancy [22]. MMP8 mRNA was elevated in skin samples of basal cell carcinoma patients compared to healthy controls [54] and in malignant thyroid neoplasms compared to benign neoplasms [60]. Similarly, Merkerova et al. [69] and Bruchova et al. [70] both noticed an up-regulation of MMP8 gene expression in the blood leukocytes of chronic myeloid leukemia patients compared to healthy controls. Additionally, they showed that MMP8 expression was not connected to hydroxyurea treatment and it can be effectively silenced in vitro, but the effects of this expression were not discussed. On the other hand, MMP8 mRNA expression was lower in gastric adenocarcinoma tumors compared to paired healthy tissue [36]. It could be that MMP8 mRNA is not stable or that the protein expression detected in tumors does not originate from cancer cells. The effects of tumoral MMP8 on cancer prognosis are illustrated in Figure 1 along with the studies on MMP8 in blood.

Figure 1. The effect of MMP8 in tumor or blood on cancer prognosis. The size of the ball is in portion to the number of publications on that cancer, the number in brackets depicts studies on mRNA or protein. The color of the ball depicts the effects of MMP8 on that cancer.

2.1.2. MMP8 Levels in the Serum or Plasma

The circulatory system refers to the organ systems that circulate blood and lymph throughout the body—both great sources of disease biomarkers. The studies on MMP8 in the circulation of cancer patients have predominantly investigated MMP8 in blood, specifically in plasma and serum. Linkov et al. [71] revealed that MMP8 levels in serum are unique to each individual, but they are also stable, indicating that especially if the baseline level of the patient was known, MMP8 could be used as a prognostic marker. No similar studies have been performed on plasma samples. Table 2 collates the studies on circulatory MMP8 in various cancers.
Table 2. Expression of matrix metalloproteinase 8 in blood and prognosis.

| Cancer              | Plasma/ Serum   | Method       | Study Size (Patients + Healthy Controls) | Expression and Prognosis                                                                 | Authors                                                                 |
|---------------------|-----------------|--------------|-----------------------------------------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Breast              | Serum           | Microarray   | 11 + 10                                  | Higher in patients with non-inflammatory breast cancer ($p = 0.007$). Associated with premenopausal status ($p = 0.06$), NPI ($p = 0.04$) and lymph node involvement ($p = 0.001$). Lower levels in patients with risk of distant metastasis ($p = 0.003$). | Li et al. 2017 [72]                                                      |
|                     | Plasma          | ELISA        | 208 + 42                                 | Higher in patients with advanced disease (Dukes classification $p < 0.001$, T status $p = 0.004$), distant metastasis ($p < 0.001$), tumor in right side of colon ($p = 0.038$). Correlation to worse overall survival ($p = 0.005$). | Decock et al. 2008 [73]                                                  |
| Colorectal          | Serum           | IFMA         | 335 + 47                                 | Higher is patients with high mGPS ($p < 0.001$). Negative correlation with tumor-infiltrating mast cells in invasive margin ($p = 0.005$) and tumor centre ($p = 0.010$). Correlation with poor cancer-specific survival ($p = 0.009$). | Decock et al. 2008 [73]                                                  |
|                     | Serum           | IFMA         | 271 + 0                                  | Higher in patients with non-inflammatory breast cancer ($p = 0.007$). Associated with premenopausal status ($p = 0.06$), NPI ($p = 0.04$) and lymph node involvement ($p = 0.001$). Lower levels in patients with risk of distant metastasis ($p = 0.003$). | Decock et al. 2008 [73]                                                  |
|                     | Serum           | IFMA         | 116 + 83                                 | Higher in patients ($p = 0.0000000015$). Correlation with TNM stage ($p = 0.00045$), T status ($p = 0.0035$), distant metastasis ($p = 0.00054$), CLR ($p = 0.0057$), necrosis ($p = 0.0024$), high neutrophil and leukocyte cell count ($p < 0.05$) and peritumoral tumor-destructing inflammatory cell infiltrate ($p = 0.041$). | Väyrynen et al. 2012 [32]                                               |
| Esophagus           | Serum           | Microarray   | 10 + 10                                  | Lower expression in patients ($p < 0.01$).                                            | Tong et al. 2018 [76]                                                   |
| Gastric             | Serum           | IFMA         | 233 + 0                                  | Higher expression in patients with intestinal cancer ($p = 0.044$). Patients with intermediate (31-131 ng/mL) serum MMP8 levels had better prognosis ($p = 0.002$). | Latinen et al. 2018 [35]                                                |
| Head and neck       | Serum           | IFMA         | 33 SCC, 175 benign + 0                   | Higher in tonsillar SCC patients compared to patients with benign tonsillar disease ($p = NR$). Trend towards favorable outcome (ns.). | Ilmarinen et al. 2017 [66]                                              |
|                     | Plasma          | IFMA         | 198 + 0                                  | Higher in patients with non-inflammatory breast cancer ($p = 0.007$). Associated with premenopausal status ($p = 0.06$), NPI ($p = 0.04$) and lymph node involvement ($p = 0.001$). Lower levels in patients with risk of distant metastasis ($p = 0.003$). | Li et al. 2017 [72]                                                      |
|                     | Plasma          | IFMA         | 136 + 0                                  | Higher in patients with non-inflammatory breast cancer ($p = 0.007$). Associated with premenopausal status ($p = 0.06$), NPI ($p = 0.04$) and lymph node involvement ($p = 0.001$). Lower levels in patients with risk of distant metastasis ($p = 0.003$). | Li et al. 2017 [72]                                                      |
|                     | Serum           | IFMA         | 59 + 0                                   | Higher than healthy persons ($p < 0.05$). Correlation with tumor stage ($p = NR$). | Kurokpat et al. 2004 [79]                                               |
|                     | Serum           | NR           | 73 + 74                                  | Higher than healthy persons, correlation with overall TNM status ($p = NR$). | Kurokpat et al. 2002 [80]                                               |
|                     | Serum           | ELISA        | 43+ 10                                   | Surgery lowers MMP-8 levels ($p = NR$).                                              | Kolomecki et al. 2001 [81]                                              |
|                     | Serum           | IFMA         | 134 + 0                                  | Worse overall survival ($p = 0.013$). Correlation to BCLC criteria ($p < 0.0001$) and tumor size ($p < 0.0001$). | Lempinen et al. 2013 [82]                                               |
|                     | Serum           | IFMA         | 117 + 0                                  | Elevated in vascular-invading ($p = 0.001$), ulcerating ($p = 0.003$) and bleeding ($p = 0.033$) Elevated in vascular-invading ($p = 0.001$), ulcerating ($p = 0.003$) and bleeding ($p = 0.033$). | Vihinen et al. 2008 [83]                                               |
|                     | Serum           | NR           | 14 + 0                                   | Elevated in carotid body cancer patients ($p = NR$).                                  | Serra et al. 2014 [84]                                                  |
|                     | Serum           | MAP kit      | 109 + 40                                 | Expression higher in cancer patients ($p = 0.0001$).                                  | Park et al. 2012 [85]                                                   |
|                     | Thyroid         | ELISA        | 22 + 0                                   | No correlation with tumor presence ($p = NR$).                                        | Komorowski et al. 2002 [86]                                             |
|                     | Urothelial      | Plasma       | 135 + 0                                  | No correlation to clinical stage or cancer specific mortality in high-grade tumors.     | Svatek et al. 2010 [87]                                                 |

Abbreviations: BCLC: Barcelona clinic liver cancer criteria; CLR: Crohn’s like lymphoid reaction; FACS: Fluorescence-activated cell sorter; (Fluorokine) MAP kit: Human MultiAnalyte Profiling Base kit, R&D Systems; IFMA: Immunofluorometric assay; IFN-α: Interferon-α therapy; LN: Lymph node; mGPS: Modified Glasgow prognostic score; NPI: Nottingham prognostic index; NR: Not reported; ns.: not significant; TNM: Tumor, node, metastasis staging.
2.1.2.1. MMP8 Levels Increase with Malignancy in HNSCC Patients

Kuropkat et al. [79,80] found higher MMP8 levels in the serum of HNSCC patients compared to healthy patients and MMP8 levels correlated with the T- and N-status and overall TNM stage (TNM classification of malignant tumors, Union for International Cancer Control’s [UICC]). Plasma MMP8 levels did not correlate with survival or lymph node involvement [78]. Further analysis showed that high MMP8 levels in plasma correlated with tumor stage IV and showed a trend (statistically not significant) towards favorable outcomes [77].

2.1.2.2. High Serum MMP8 Level in Digestive System Cancers Predict Worse Prognosis

High serum MMP8 levels seem to hinder the survival of patients with various cancers of the digestive and urinary systems. In colorectal cancer patients, increased serum MMP8 levels were measured compared to healthy controls and a high MMP8 level correlated with malignancy, reduced survival and increased systemic inflammation [32,74,75]. Moreover, in hepatocellular carcinoma, low serum MMP8 levels correlated with better overall survival [82]. In pancreatic and kidney cancer patients, serum MMP8 levels were increased compared to healthy controls but no correlation to any clinicopathological features was found [81,85]. Interestingly, low or high MMP8 serum levels correlated with poor prognosis in gastric cancer patients [35]. In regard to esophageal cancer, MMP8 levels were significantly lower in serum samples from early stage patients compared to healthy controls [76]. MMP8 levels in plasma showed no correlation to clinical stage or cancer-related mortality in bladder cancer patients [87].

2.1.2.3. The Prognostic Value of Circulating MMP8 Levels in Other Cancers Requires More Studies

In breast cancer patients, serum MMP8 levels were higher compared to healthy controls [72]. MMP8 expression in plasma was higher in patients with non-inflammatory breast cancer as well as in patients with lymph node involvement, but interestingly, lower in patients with risk of distant metastasis [73]. Similarly, higher plasma MMP8 levels were demonstrated in carotid body paraganglioma patients compared to healthy persons, but not patients with malignant disease [84]. Low serum MMP8 levels in melanoma patients correlated with better overall survival [83]. Serum MMP8 levels did not correlate with the presence of tumors in thyroid cancer patients [86]. High MMP8 expression, measured only from circulating tumor cells, in the blood of metastatic castration-resistant prostate cancer patients correlated with lower overall survival [88]. In lung cancer, measuring MMP8 levels in bronchial washings had no value in terms of detection [89].

2.1.3. Genetics of MMP8 in Cancer

Cancer is a genetic disease in origin and various mutations, polymorphisms and DNA copy number variances have been detected in different cancers. Studies on MMP8 genetics in cancer have focused largely on single nucleotide polymorphisms (SNPs), which are collected in Table 3. Figure 2 illustrates the locations of studied SNPs in relation to the MMP8 gene.

Figure 2. Schematic illustration of MMP8 including the studied single nucleotide polymorphisms (SNPs).
### Table 3. Matrix metalloproteinase 8 SNPs and prognosis.

| Cancer         | SNPs                                                                 | Study Size (Patients + Healthy Controls) | Effect on Patient (p-Value)                                                                 | Authors                                                                 |
|----------------|-----------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Bladder        | rs11225395, rs35866072, rs34009635                                     | 375 + 375                               | No effect on bladder cancer risk.                                                           | Tsai et al. 2018 [90]                                                  |
|                | rs11225395                                                            | 200 + 200                               | Reduced risk of bladder cancer (p = 0.006).                                                | Srivastava et al. 2013 [91]                                           |
|                | rs1940475                                                             | 243 invasive, 315 superficial            | Protects from invasive phenotype in former smokers (p = 0.05).                             | Kader et al. 2007 [92]                                                |
|                | rs1940475                                                             | 560 + 560                               | Trend to increased risk of invasive bladder cancer in never smokers (ns.).                  | Kader et al. 2006 [93]                                                |
| Breast         | rs11225395, rs35866072, rs34009635                                     | 1232 + 1232                             | No effect on breast cancer risk.                                                           | Hsiao et al. 2018 [94]                                                |
|                | rs11225395                                                            | 6307 + 0                                | Better overall survival (p = 0.021).                                                      | Beeghly-Fadiel et al. 2012 [95]                                       |
|                | rs1940475                                                             | 300 + 300                               | Not associated with breast cancer risk.                                                    | Dębniak et al. 2011 [96]                                              |
|                | rs11225395, rs35866072, rs34009635                                     | 4470 + 4560                             | rs11225395: Associated with breast cancer (p = 0.0097).                                  | Mavaddat et al. 2009 [97]                                            |
|                | rs1940475                                                             | 560 + 560                               | rs11225395, rs1940475 and rs1276284: Less metastasis (p = 0.02, p = 0.03, p = 0.03, respectively). Higher overall (p = 0.02) and disease-specific survival (p = 0.02) and less relapse (p = 0.04) in early stage patients. | Decock et al. 2007 [98]                                              |
| Head and neck  | rs11225395, rs35866072, rs34009635                                     | 79 + 169                                | No correlation to risk or clinicopathological parameters.                                | Kubben et al. 2006 [99]                                              |
|                | rs11225395                                                            | 788 + 956                               | No effect on oral cancer risk.                                                            | Hung et al. 2017 [100]                                               |
|                | rs11225395                                                            | 198 + 0                                 | No significant effect on overall survival in NPC.                                          | Liu et al. 2013 [101]                                                |
| Leukemia       | rs11225395, rs35866072, rs34009635                                     | 266 + 266                               | No correlation to survival or LNM in HNSCC patients.                                       | Pradhan-Palikhe et al. 2010 [78]                                      |
|                | rs11225395                                                            | 434 + 480                               | No effect on childhood leukemia risk.                                                      | Qiu et al. 2008 [103]                                                |
|                | rs11225395, rs35866072, rs34009635                                     | 358 + 716                               | Increased risk of HCC in non-HBV carriers (p = 0.03).                                      | Shen et al. 2017 [104]                                               |
|                | rs11225395, rs35866072, rs34009635                                     | 501 + 510                               | Reduced risk on lung cancer risk.                                                         | Gonzalez-Arriaga et al. 2008 [105]                                   |
| Ovarian        | rs11225395, rs35866072, rs34009635                                     | 35 malignant, 51 benign + 37            | Reduced overall survival (p = 0.0257).                                                    | Wang et al. 2015 [106]                                               |
|                | rs11225395, rs35866072, rs34009635                                     | 35125395: Increased risk for ovarian cancer (p = 0.02) and tendency towards worse overall survival (ns.). | Arechavaleta-Velasco et al. 2014 [107]                                                 |
| Skin           | rs11225395                                                            | 285 SCC, 300 BCC, 218 melanoma + 870    | Reduced risk for BCC (p = 0.04), no effect in SCC or melanoma.                            | Nan et al. 2008 [108]                                                |
| Thyroid        | rs11225395                                                            | 300 melanoma + 300                      | Increased risk for melanoma (p = 0.017).                                                   | Dębniak et al. 2011 [96]                                              |
|                | rs11225395                                                            | 31 PTC, 19 FTC and 9 ATC + 0            | Present in 80.6% of PTC, 73.6% of FTC and 88.8% of ATC tumors.                           | Murugan et al. 2011 [109]                                            |

Abbreviations: ATC: Anaplastic thyroid carcinoma; BCC: Basal cell carcinoma; FTC: Follicular thyroid carcinoma; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HNSCC: Head and neck squamous cell carcinoma; LNM: Lymph node metastasis; NPC: Nasopharyngeal cancer; ns.: not significant; PTC: Papillary thyroid carcinoma; SCC: Squamous cell carcinoma.
2.1.3.1. The SNP rs1122539 Protects from Breast and Bladder Cancer but Increases the Risk of Melanoma and Ovarian Cancer

The most studied SNP in the MMP8 gene is SNP rs11225395 (C-799T) located in the promoter region that increases the transcription of MMP8 [98]. SNP rs11225395 is associated with a lower risk of developing breast cancer and a higher overall survival from breast cancer as shown by three independent studies [95,96,98]. Yet Hsiao et al. [94] found no correlation with breast cancer risk in their population. Another study found that the same SNP correlated with reduced risk of bladder cancer, even in smokers, but was not associated with tumor grade [91].

In contrast, SNP rs11225395 was associated with an increased risk of developing melanoma [96] and ovarian cancer. Moreover, in ovarian cancer, a tendency towards worse overall survival was found [107]. In the case of HNSCC, no correlation between SNP rs11225395 and survival of the patients was found [78], nor was this SNP associated with risk of oral cancer [100]. Studies on the susceptibility to hepatocellular carcinoma [103], bladder cancer [90], acute lymphatic leukemia in children [102] and lung cancer [104] revealed no correlation to SNP rs11225395.

2.1.3.2. Fluctuating Findings on the Effect of SNP rs1940475

The SNP rs1940475 (A259G) is located in the pro-domain of MMP8 and alters the structural stability of the domain, thus decreasing the activation of MMP8 [110]. Murugan et al. [109] revealed that 73.6–88.8% of their thyroid carcinoma tumor samples harbored SNP rs1940475 and the authors postulated, based on the location of this SNP, an effect on the function of MMP8. Later Lin et al. [36] showed decreased enzymatic activity of MMP8 harboring this SNP as well as increased recurrence and lower survival of gastric adenocarcinoma patients. Yet Kader et al. [92,93] found no correlation with the risk of bladder cancer or its type to SNP rs1940475. Interestingly though, this SNP had a seemingly protective effect in former smokers, but in never smokers there was a trend of increased risk of invasive bladder cancer. Nan et al. [111] associated SNP rs1940475 with the risk of basal cell carcinoma (but not SCC or melanoma) but the association was not significant in age-adjusted analysis. Based on the studies, these cancers might benefit from having a MMP8-inactivating SNP suggesting that MMP8 is a tumor-protective factor in them.

2.1.3.3. Other MMP8 SNPs Also Decrease Cancer Risks

Gonzalez-Arriaga et al. [105] found that SNP rs2155052 (C17G) in the MMP8 promoter region is associated with decreased risk of lung cancer, especially in high-risk patients such as ever-smokers. An intronic SNP rs1892886 is associated with breast cancer [97] and was also found to have a lower frequency in patients with lymph node metastasis [98], along with SNPs rs11225395, rs1940475 and rs1276284. On the contrary to other studies, SNP rs17099462 decreased the expression of MMP8 and was shown to be associated with the increased risk of death from ovarian cancer [106]. MMP8 SNPs rs35866072 and rs34009635 have no effect on the risks of childhood acute lymphocytic leukemia [102], breast [94], bladder [90], oral [100] or lung cancer [104]. No MMP8 SNPs were correlated to nasopharyngeal carcinoma [101] or gastric cancer and its clinicopathological features [99].

2.1.3.4. Studies on Somatic and Epigenetic Changes Strengthen the View of Active MMP8 as a Tumor-Suppressive Factor

Only a few genetic studies on MMP8 other than SNP analyses have been reported. Palavalli et al. [112] found that melanomas harbor somatic MMP8 mutations, which decrease MMP8 activity and lead to increased colony formation and cell migration in vitro as well as metastasis formation in vivo. Accordingly, a microarray analysis of the epigenetic regulation of MMPs in breast cancer and glioma cell lines revealed an epigenetic inactivation of MMP8 unlike other MMPs, which could explain the reduction of active MMP8 in various malignancies unrelated to their genetics [113]. For miRNA studies, miR-539 was shown to directly target MMP8 3′-UTR along with other targets thus inhibiting MMP8 expression. In osteosarcoma cells, the overexpression of this miRNA led to
reduced proliferation, invasion and migration, suggesting MMP8 acts as a tumor-promoting factor in osteosarcoma [114].

2.2. In Vitro Experimental Evidence and In Vivo Mouse Studies Elucidate the Molecular Mechanisms of MMP8 in Cancers

2.2.1. Studies in Skin Cancer Paved the Way for the Idea of Tumor-Suppressive MMP8

In vitro studies on skin cancer revealed that most melanoma cell lines, but not normal melanocytes, express MMP8 mRNA [57]. Yet at the protein level, MMP8 was only present in half of the nine melanoma cell lines examined by Giricz et al. [115]. Similarly, MMP8 mRNA expression in keratinocytes of varying tumorigenic potential was detected in vitro but protein expression varied [116].

In vivo murine studies paint a clearer picture; male MMP8 knock-out (KO) mice were more prone to carcinogen-induced skin and connective tissue cancers than the wild-type mice and the protective effect of MMP8 could be restored by a bone marrow transplant from wild-type mice [117]. Subsequently, MMP8 KO mice were also shown to be susceptible to melanoma [27]. Murine melanoma cells, B16F10, formed more lung metastases in MMP8 KO mice, whereas the overexpression of MMP8 in tumor cells lowered the number and size of metastases. MMP8 was also upregulated in the secretome of DNA-dependent protein kinase, catalytic subunit (DNA-PKcs)-silenced melanoma cells that metastasized less in vivo and migrated/invaded less in vitro [118], providing indirect evidence for the protective role of MMP8. However, in B16F10-derived melanoma in C-C chemokine receptor 5 KO mice, MMP8 had no effect on metastasis [119].

2.2.2. MMP8 Has Fluctuating Expression Profiles in Breast Cancer Cells In Vitro, but Rather Consistent Tumor-Protective Effects In Vivo

Overall MMP levels increase during malignant transformation in breast cancer cell lines—so does MMP8 as well [120]. Most studies [121–123], apart from Agarwal et al. [124], show that the non-metastatic MCF-7 cell line produces no endogenous MMP8 protein. Yet, notoriously metastatic MDA-MB-435, as well as less metastatic MDA-MB-468 [26,121] and MDA-MB-231 cells [122], do produce MMP8. MMP8 mRNA expression is only detected in MDA-MB-231 cells [121,123,124], except in one study that found no expression [125]. Co-culture with adipose tissue-derived mesenchymal stem cells, a driver of tumorigenesis, did not affect the MMP8 expression of breast cancer cells [126]. Although MMP8 was mainly found to be expressed by metastatic cell lines and not the non-metastatic MCF-7 cell line, many [123,124,127] have shown that MMP8-expressing breast cancer cell lines are less invasive in vitro and generate less metastases in mice in vivo. Similar conclusions were drawn by Decock et al. [128] and Soria-Valles et al. [129] in their studies on MMP8 KO mice. Systemic MMP8 expression was found to decrease tumor size, hinder tumorigenesis and protect from metastasis formation. Moreover, xenografted tumors in MMP8-deficient mice showed decreased vascularization and neutrophil recruitment [128]. In their studies, MMP8 cleaved decorin, which inhibits TGF-β1: The subsequent downregulation of miR-21 expression led to activation of known tumor suppressors such as programmed cell death 4 (PDCD4) [129]. MMP8 has also been shown to affect the protease web by, e.g., decreasing the levels of MMP3 [128] and MMP9 [62] in breast cancer cells, which was speculated to decrease the malignant behavior of the cells [128]. Furthermore, MMP8 overexpression was shown to increase the expression of interleukins 6 and 8 in breast cancer cells [123], which was postulated to be connected to inflammatory response rather than cancer progression. Accordingly, MMP8 overexpressing breast cancer cells had reduced migratory and proliferative properties in vitro [129]. Similarly, MMP8 overexpressing breast myoepithelial cells show increased adhesion, due to retraction fiber shortening and differential localization of integrin α6β4 [62]. The variable results might be explained by heterogeneity between cell lines, sensitivity differences between methods, or as shown by Bachmeier et al. [121]; confluence of the cell culture. However, MMP8 was shown not to be involved in the tumor-promoting effects of TLR9 and relaxin that induced the activity of many MMPs in breast cancer cells thereby increasing cell invasiveness [130,131]. In contrast, tumor-induced systemic
inflammation in breast cancer increased metastasis generation in mice due to neutrophil-mediated tumor cell extravasation and inhibition of tumor cell clearance. Additionally, these neutrophils were shown to secrete increased amounts of MMP8 and MMP9, which facilitated tumor cell extravasation and metastasis [132]. Thus, MMP8 expression, although low in non-malignant breast cancer cells, seems to act as a tumor suppressor rather than an enhancer in malignant cells but not in neutrophils. It is important to note that factors elevated during cancer progression should not be interpreted as tumor promoters.

2.2.3. Tumor-Protective Molecular Mechanisms of MMP8

Several studies show that MMP8 triggers tumor-suppressive molecular cascades after cleavage of various non-ECM substrates, as shown in Figure 3. Indeed, it has also been shown that collagenolytic activity did not decrease in fibroblasts isolated from MMP8 KO mice [133], suggesting other MMPs than MMP8 were the source of collagenolysis in vivo. However, Korpi et al. [44] found that female MMP8 KO mice are especially prone to carcinogen-induced tongue cancer and that MMP8 cleaves estrogen receptors α and β. Later, MMP8 overexpression was shown to reduce the invasion and migration of OTSCC cells in vitro and to change the gene and protein expression of various factors, including a decrease in VEGF-C [39]. Lung adenocarcinoma cells treated with hepatocyte growth factor variants showed inhibition of proliferation, reduced invasion and increased amounts of active MMP8, which was suggested to facilitate the tumor-protective effects [134]. On the other hand, MMP8 mRNA expression increased along other MMPs in aggressive lung cancer cell lines resistant to targeted chemotherapy [135]. Additionally, Pellinen et al. [136] showed that silencing of MMP8 in prostate cancer cells led to increased ligand binding of β1 integrin and higher prostate cancer cell invasion in vitro as well as increased breast cancer lung extravasation in vivo. Yet overexpression of integrin α6β4 in OSCC cells did not change MMP8 mRNA expression, which shows, that MMP8 affects integrin but not vice versa [137].

![Figure 3. Suggested molecular mechanisms of MMP8. Abbreviations: Akt: RAC-α serine/threonine-protein kinase; Arf1: ADP-ribosylation factor 1; ECM: Extracellular matrix; EphB2: Ephrin type B receptor 2; ER-α/β: Estrogen receptor α/β; IL-6/8: Interleukin 6/8; MMP3: Matrix metalloproteinase 3; MMP8: Matrix metalloproteinase 8; PDCD4: Programmed cell death 4; PI3K: Phosphoinositide 3-kinase; TGF-β: Transforming growth factor β receptor; TGF-β1: Transforming growth factor β-1. See references (in superscript) for original publications.](image-url)
2.2.4. Tumor-Promoting Molecular Mechanisms of MMP8

MMP8 exhibits some pro-tumorigenic effects through substrate cleavage: Ephrin-B1 belongs to an ephrin family of proteins, which transduce signals related to cell adhesion and angiogenesis [138]. The intracellular C-terminus of ephrin-B1, that is required for invasion of pancreatic cancer cells in vitro and in vivo in mice, was shown to regulate the release of MMP8 from these cells via activation of the cell trafficking regulator, Arf1 [139]. Furthermore, the released MMP8 could cleave the ectodomain of ephrin-B1, in a potential feedback mechanism to downregulate the activity of ephrin-B1. Later it was shown that a peptide from the ephrin-B1 C-terminus can block the release of MMP8 and can inhibit the invasion of gastric scirrhous carcinoma cells in vitro and their peritoneal dissemination in vivo [140]. Although MMP8 in vitro was shown to cleave laminin5 γ2-chains (a basal membrane component known to induce migration when cleaved), its addition to MCF-7 breast cancer cells had no impact on their migration over laminin [141].

Other pro-tumorigenic effects of MMP8 may be linked to signaling properties of MMP8: MMP8 itself upregulates TGF-β1 expression by activating the PI3K/Akt/Rac1-pathway, which in turn leads to an epithelial-mesenchymal transition (EMT), and subsequently, increased invasion and migration of hepatocellular carcinoma cells [48]. Bone marrow cells produce MMP8 along with other MMPs during multiple myeloma progression in vivo and the tumor growth can be reduced with the broad spectrum MMP inhibitor; SC-964 [142]. Various factors known to promote tumorigenesis were shown to increase MMP8 expression or activity in vitro: CD44- and CD24-expressing renal cell carcinoma stem cell subsets, serpinA1-expressing gastric cancer cells and CCL25-expressing ovarian cancer cells all showed higher migratory and invasive potential in vitro as well as higher MMP8 expression [143–145]. Interestingly, in prostate cancer cells, no MMP8 was detected even after induction with CCL25 [146]. In vitro in OSCC cells, betel quid increased MMP8 levels and cell migration [147], whereas trypsin-2 activated MMP8 [148]. Yet, endostatin, anti-angiogenic collagen XVIII fragment had no inhibitory effect on MMP8 although it could inhibit migration [149]. However, none of these studies examined how changes in the level of MMP8 affected the cancer cells.

2.2.5. MMP8 Expression Is Not Detected at All in Some Cancer Cell Lines

In some cancer cell lines, no MMP8 mRNA was detected, such as in bladder cancer [150], Ewing’s sarcoma [151], chondrosarcoma [152] or follicular thyroid carcinoma cells [153], and thus, the mechanistic role of MMP8 in those cancers has not been examined. Additionally, no MMP8 gene expression was found in stellate cells—building blocks of the ECM in pancreatic cancer [154]. In renal cell carcinoma, no differences in MMP8 gene expression were detected between healthy and cancerous kidney tissue as well as bone metastasis [155]. MMP8 expression is detected in fibrosarcoma cell lines, but not in the in vivo chorioallantoic membrane (CAM) assay, which is used to study tumor angiogenesis and invasion [156].

2.3. The Potential of MMP8 in Cancer Treatment

2.3.1. Using MMP8 as a Pharmaceutical Adjuvant Shows Promising Results

Three independent studies show that MMP8 reduces interstitial tumor fluid pressure, increases fluid flow in various murine tumors, namely lung cancer, soft tissue sarcoma and HNSCC, and enhances the efficacies of oncolytic virus therapy and liposomal drugs [157–159]. Thus, MMP8 could be a potential adjuvant drug. Additionally, varying levels of MMPs, MMP8 included, can be visualized with tomography methods in breast cancer tumors in vivo (murine), offering a diagnostic tool to evaluate tumor progression and heterogeneity [160].

2.3.2. Cancer Treatments Affect MMP8 Levels in Tumors

Many cancer drugs can decrease MMP8 levels along with other MMPs: The plant-based isoflavones genistein and glycitein, as well as the flavone apigenin, down-regulate MMP8 expression in vitro and
inhibit leukemia cell invasion [161,162] and decrease the viability of hepatocellular carcinoma cells [163]. Saponins from the plant Rhizoma paridis decreased the expression of inflammatory cytokines and MMP8 as well as reduced lung cancer tumor volume and growth in mice [164]. Therapeutic gold nanoparticles, which decreased ovarian cancer tumor growth and metastasis in vivo, also inhibited ovarian cancer cell proliferation, decreased MMP8 expression, and altered cytokine production in vitro [165]. Treatment with the cytotoxic peptide HNP-1 reduced the levels of MMP8 as well as increased lactate dehydrogenase toxicity in OSCC cell lines but did not affect cell viability [166]. Reduced levels of MMP8 were observed when glioblastoma multiforme spheroids were treated with 5-aminolevulinic acid-photodynamic therapy [167]. MMP8 levels in blood decreased after tumor removal in paraganglioma [168] and pancreatic ductal adenocarcinoma patients [85]. Systemic changes in MMP8 levels after cancer treatment might be explained by the changes in systemic inflammation.

On the other hand, several studies show that some cancer treatments may also increase MMP8 levels: Increased expression of proangiogenic factors, including MMP8, by myeloid derived suppressor cells could contribute to resistance to Sunitinib treatment seen in some kidney cancer patients [169]. Treatment of bladder cancer with bacterial CBM588 strongly inhibited the tumor growth in vivo in mice, which was suggested to be due to the release of TNF-related apoptosis-inducing ligand (TRAIL) from PMN cells by MMP8 [170]. An in vitro prostate cancer study by Reel et al. [171] showed that Zoledronate, an inhibitor of osteoclastic bone resorption, downregulates discoidin domain receptor proteins—known MMP activators. Subsequently, the MMP levels were downregulated except for MMP8, which increased. The progesterone receptor modulator CDB-2914, induces MMP expression, including MMP8, in uterine leiomyoma cells, but MMP8 is not activated by this treatment and its role remains unclear [172]. In skin cancer, immunosuppression does not change MMP8 expression levels or its location [173], nor did MMP8 expression in skin SCC tumors correlate with its aggressiveness in immunosuppressed transplant patients [64].

2.3.3. High MMP8 Levels Can Guide Treatment Choices and Indicate Harmful Post-Operative Reactions in Some Patients

High serum MMP8 levels could be used to define cutaneous melanoma patients who would benefit from interferon-α (IFN-α) therapy [174]. Yet Van Roy et al. [175] showed earlier that MMP8 deficiency does not change the survival of mice inoculated with B16BL6 melanoma tumor cells and treated with TNF/IFNγ therapy. Lin et al. [176] showed that prostate cancer patients with MMP8 SNP rs11225395 benefit more from androgen deprivation therapy than other patients.

MMP8 levels in some body fluids can also be used to assess post-operative reactions: HNSCC patients, who developed radiochemotherapy-induced oral mucositis, had a higher salivary MMP8 level than those who did not develop this reaction [177]. Elevated MMP8 levels in intraperitoneal fluid were also seen in rectal cancer patients who developed anastomotic leakage after surgery [178].

2.3.4. MMP8 as an Anti-Target for MMP Inhibitors

Inhibition of MMPs has been considered as a potential clinical intervention in cancer treatment. The first synthetic MMP inhibitors (MMPIs); Batimastat (BB-94) and Marimastat (BB-2516), were developed almost 20 years ago and they showed promising results in murine studies, e.g., by reducing the tumor volume in ovarian cancer [179]. They were rushed to clinical trials and disappointment ensued—no effects on tumors were seen, yet the side effects for patients, such as pain in bones, were significant [180]. Recently, the development of MMPIs has moved away from general MMPIs [181–183] towards specific inhibitors for MMP1 [184], gelatinases [185–187], MMP11 [188] and specific cancers [189] or stages of tumor progression [190]. However, specificity is an issue due to the high level of sequence and structural homology between MMPs, and some of these “specific” inhibitors also bind MMP8. Previously, inhibitors were designed specifically for MMP8 [191]. Since the tumor-protective effects were demonstrated in 2003, MMP8 has been regarded as an anti-target in MMP inhibitor development [192–194]. However, MMP8 expression has also been shown to increase in highly
vascularized tissues such as tumor and placenta [195] and this protease is generally regarded as a proangiogenic factor. Angiogenesis is a major target in cancer treatment and MMPIs have been developed against proangiogenic MMPs such as MMP8 and MMP9 [108,196].

3. Discussion

In this systematic review we gathered the available data from the Scopus database on the role of MMP8 in cancer, including the use of MMP8 as a biomarker for prognosis in tumors, blood, and at the genetic level, in vivo and in vitro studies on its molecular mechanisms as well as its use in cancer therapy. The limitation of the study is the use of one database only. In addition, given the large number of studies included an in-depth analysis of individual studies was prevented. Meta-analyses were not performed due to the high variability between different studies as well as the poor number of studies per cancer type.

In general, MMP8 levels in tumors variate and are not always detected. The studies published to date, suggest that high MMP8 protein levels might predict better survival for tongue [39,44] and some breast [27] cancer patients, but they provide a worse prognosis in hepatocellular [48] and ovarian [50,51] cancers. Results variate greatly for some, such as colorectal cancer [31–34]. However, mRNA levels are even more inconsistent. This phenomenon can partly be explained by different sources of MMP8 in the body, such as tumor cells and neutrophils. Not all studies state where the analyzed MMP8 staining is localized (tumor cells, neutrophils, tumor stroma, etc.), which might partly explain the inconsistency. The presence of cancer seems to increase the level of MMP8 in circulation and depending on the cancer, high plasma MMP8 levels might be beneficial (e.g., breast cancer [73]), but in some cancers (colorectal [32,74,75], hepatocellular [82] and melanoma [83]) high serum MMP8 levels correlate with poor prognosis. Additionally, it should be noted that serum and plasma may give contradicting results; plasma contains blood cells including neutrophils, which might release additional MMP8 in the sample after collection. SNPs, which modulate MMP8 transcription and activity, seem to play the strongest role in cancer prognosis and are beneficial for breast [95,98], bladder [91,93] and gastric [36] cancer patients but detrimental in ovarian [107] cancer patients. Other SNPs and genetic modifications have been poorly studied or do not correlate with clinicopathological parameters.

In vitro experiments and in vivo murine studies shed light on the non-collagenolytic actions of MMP8 and strengthen the findings from in vivo patient data. These studies were the first to introduce the idea of tumor-protective MMP8 in skin cancer [27,117] and breast cancer [124,127–129]. In these cancers, MMP8 slows the metastatic process both in vivo and in vitro, which explains why patients benefit from MMP8. Studies have also revealed non-collagen substrates for MMP8 including transmembrane proteins, cytokines and signaling molecules. However, MMP8 activity can also be harmful, as shown for pancreatic and gastric cancers [138,140], in which the interaction between MMP8 and Ephrin-B1 seems crucial, and hepatocellular carcinoma [48], where MMP8 was shown to activate the PI3K/Akt/Rac1 pathway.

MMP8 is nowadays considered an anti-target in cancer drug development. However, many cancer therapies modulate MMP8 levels—this might present changes in systemic inflammation. The use of MMP8 in treatment selection and for the evaluation of harmful post-operative reactions has not been fully examined in various cancers but it might be useful in those cancers where MMP8 has been shown to play a role. The use of MMP8 as an adjuvant [157–159] in cancer drug treatment poses unappreciated potential and should be further studied.

The role of MMP8 seems more definite in those cancers, that are well studied—e.g., the effects of MMP8 in breast cancer is studied in more than 30 research articles. When the tumor-protective role of MMP8—a novel function for proteases at that time, was first reported in 2003 in breast and skin cancers, it probably increased the interest in the role of MMP8 specifically in those cancers. However, to evaluate the overall function of MMP8 in various steps of cancer progression, the tumor-promoting mechanisms of this multifunctional enzyme should also be studied.
4. Materials and Methods

This article was compiled by following the systematic review guide—Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [197]. The workflow is depicted in Figure 4. Searches were run using the Scopus (https://www.scopus.com) database with the assistance of an information specialist. The search terms MMP8 (mmp 8 OR matrix metalloproteinase 8 OR neutrophil collagenase OR collagenase 2) and cancer (cancer OR neoplasm* OR carcinoma* OR malignan* OR tumor* OR sarcoma* OR leukemi* OR lymphoma* OR adenocarcinoma*) were searched from titles, abstracts and keywords, where the asterisk (*) is used to indicate truncation and the question mark (?) is used to indicate wildcard characters.

A total of 692 hits were retrieved. Next, articles written in languages other than English, published before 1st January, 1990 and after 1st January, 2019 or which were not original research articles were excluded. After the first exclusion, the abstracts of the remaining 431 articles were carefully analyzed. After an abstract review, articles were excluded if they were a review, or if MMP8 was not studied, or if the study did not focus on cancer—leading to 168 collected articles. The articles excluded by Scopus (217) were manually checked and three articles were returned. Thus, a total of 171 articles were included in this systematic review. To answer our specific research questions (“can MMP8 be used as a prognostic factor in cancer?”; “what are the molecular mechanisms of MMP8 in cancer?”; and “can MMP8 be used in cancer treatment?”) the information about study size and type, methodology, patient outcome, main findings and statistical results were retrieved.

Author Contributions: Conceptualization and methodology, K.J., T.S., P.N. and P.Å.; investigation, formal analysis, K.J., P.Å.; writing—original draft preparation and visualization, K.J.; validation, writing—review and editing K.J., G.S.B., T.S., P.N. and P.Å.; supervision, T.S. and P.N.; project administration, P.N. and P.Å.; funding acquisition, T.S., P.N. and P.Å.

Funding: This research was funded by Sigrid Juselius Foundation (K.J., T.S., P.Å.), Oulu University Hospital (K.J., P.N., grant number K10755), Cancer Society of Finland (T.S.) and Academy of Finland (P.Å., grant number 308363).
Acknowledgments: We thank the personnel at the library of University of Oulu for their help in conducting the literature search.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| DFS          | Disease-free survival |
| ECM          | Extracellular matrix |
| EMT          | Epithelial-mesenchymal transition |
| HNSCC        | Head and neck squamous cell carcinoma |
| MMP          | Matrix metalloproteinase |
| MMP8         | Matrix metalloproteinase 8 |
| MMPI         | Matrix metalloproteinase inhibitor |
| OS           | Overall survival |
| OSCC         | Oral squamous cell carcinoma |
| OTSCC        | Oral tongue squamous cell carcinoma |
| PMN          | Polymorphonuclear neutrophils |
| RFS          | Recurrence- or relapse-free survival |
| SCC          | Squamous cell carcinoma |
| SNP          | Single nucleotide polymorphism |
| TGF-β1       | Transforming growth factor β1 |
| TIMP-1       | Metalloproteinase inhibitor 1 |
| VEGF-C       | Vascular endothelial growth factor C |

References

1. Ahmad, A.S.; Ormiston-Smith, N.; Sasieni, P.D. Trends in the lifetime risk of developing cancer in Great Britain: Comparison of risk for those born from 1930 to 1960. *Br. J. Cancer* **2015**, *112*, 943–947. [CrossRef] [PubMed]

2. Allemani, C.; Matsuda, T.; di Carlo, V.; Harewood, R.; Matz, M.; Nikšić, M.; Bonaventure, A.; Valkov, M.; Johnson, C.J.; Estève, J.; et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet* **2018**, *391*, 1023–1075. [CrossRef]

3. Wild, C.P. The global cancer burden: Necessity is the mother of prevention. *Nat. Rev. Cancer* **2019**, *19*, 123–124. [CrossRef] [PubMed]

4. Chie, W.; Chang, Y.; Chen, H. A novel method for evaluation of improved survival trend for common cancer: Early detection or improvement of medical care. *J. Eval. Clin. Pract.* **2007**, *13*, 79–85. [CrossRef] [PubMed]

5. Walters, S.; Benitez-Majano, S.; Muller, P.; Coleman, M.P.; Allemani, C.; Butler, J.; Peake, M.; Guren, M.G.; Cimelius, B.; Bergström, S.; et al. Is England closing the international gap in cancer survival? *Br. J. Cancer* **2015**, *113*, 848. [CrossRef] [PubMed]

6. Ludwig, J.A.; Weinstein, J.N. Biomarkers in Cancer Staging, Prognosis and Treatment Selection. *Nat. Rev. Cancer* **2005**, *5*, 845. [CrossRef] [PubMed]

7. Goossens, N.; Nakagawa, S.; Sun, X.; Hoshida, Y. Cancer biomarker discovery and validation. *Transl. Cancer Res.* **2015**, *4*, 256–269.

8. Roy, R.; Yang, J.; Moses, M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. *Off. J. Am. Soc. Clin. Oncol.* **2009**, *27*, 5287–5297. [CrossRef]

9. Liotta, L.A.; Tryggvason, K.; Garbisa, S.; Hart, I.; Foltz, C.M.; Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. *Nature* **1980**, *284*, 67–68. [CrossRef]

10. Kapoor, C.; Vaidya, S.; Wadhwan, V.H.; Kaur, G.; Pathak, A. Seesaw of matrix metalloproteinases (MMPs). *J. Caner Res. Ther.* **2016**, *12*, 28–35. [CrossRef]

11. Sorsa, T.; Gursoy, U.K.; Nwhator, S.; Hernandez, M.; Tervahartiala, T.; Leppilahti, J.; Gursoy, M.; Könönen, E.; Emingil, G.; Pussinen, P.J.; et al. Analysis of matrix metalloproteinases, especially MMP-8, in gingival crevicular fluid, mouthrinse and saliva for monitoring periodontal diseases. *Periodontol* **2000** **2016**, *70*, 142–163. [CrossRef] [PubMed]
12. Kim, J.; Jeong, Y.; Lee, E.; Park, J.; Seo, H.; Kim, H. Suppression of neuroinflammation by matrix metalloproteinase-8 inhibitor in aged normal and LRRK2 G2019S Parkinson’s disease model mice challenged with lipopolysaccharide. *Biochem. Biophys. Res. Commun.* 2017, 493, 879–886. [CrossRef] [PubMed]

13. Cox, J.H.; Starr, A.E.; Kappelhoff, R.; Yan, R.; Roberts, C.R.; Overall, C.M. Matrix metalloproteinase 8 deficiency in mice exacerbates inflammatory arthritis through delayed neutrophil apoptosis and reduced caspase 11 expression. *Arthritis Rheum.* 2010, 62, 3645–3655. [CrossRef] [PubMed]

14. Rojas-Quintero, J.; Owen, C. Matrix metalloproteinases in cystic fibrosis: Pathophysiological and therapeutic perspectives. *Met. Med.* 2016, 3, 49–62.

15. Van Lint, P.; Libert, C. Matrix metalloproteinase-8: Cleavage can be decisive. *Cytokine Growth Factor Rev.* 2006, 17, 217–223. [CrossRef] [PubMed]

16. Ala-aho, R.; Kähäri, V. Collagenases in cancer. *Biochimie* 2005, 87, 273–286. [CrossRef]

17. Kim, S.; Roh, J.; Park, C. Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips. *J. Pathol. Transl. Med.* 2016, 50, 411–418. [CrossRef]

18. Ikeda, K.; Monden, T.; Kanoh, T.; Tsujie, M.; Izawa, H.; Haba, A.; Ohnishi, T.; Sekimoto, M.; Tomita, N.; Shiozaki, H.; et al. Extraction and Analysis of Diagnostically Useful Proteins from Formalin-fixed, Paraffin-embedded Tissue Sections. *J. Histochem. Cytochem.* 1998, 46, 397–403. [CrossRef]

19. Kampf, C.; Olsson, I.; Ryberg, U.; Sjöstedt, E.; Pontén, F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. *J. Vis. Exp. JoVE* 2012, 31, e3620. [CrossRef]

20. Bernard, P.S.; Wittwer, C.T. Real-Time PCR Technology for Cancer Diagnostics. *Clin. Chem.* 2002, 48, 1178.

21. Jensen, E. Technical Review: In Situ Hybridization. *Anat. Rec.* 2014, 297, 1349–1353. [CrossRef] [PubMed]

22. Wallard, M.J.; Pennington, C.J.; Veerakumarasivam, A.; Burtt, G.; Mills, I.G.; Warren, A.; Leung, H.Y.; Murphy, G.; Edwards, D.R.; Neal, D.E.; et al. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. *Br. J. Cancer* 2006, 94, 569–577. [CrossRef] [PubMed]

23. Korpi, J.T.; Hagström, J.; Lehtonen, N.; Parkkinen, J.; Sorsa, T.; Salo, T.; Laitinen, M. Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. *Surg. Oncol.* 2011, 20, e18–e22. [CrossRef] [PubMed]

24. Scully, S.P.; Berend, K.R.; Qi, W.; Harrelson, J.M. Collagenase specificity in chondrosarcoma metastasis. *Braz. J. Med. Biol. Res.* 1999, 32, 885–889. [CrossRef] [PubMed]

25. Benson, C.S.; Babu, S.D.; Radhakrishna, S.; Selvamurugan, N.; Sankar, B.R. Expression of matrix metalloproteinases in human breast cancer tissues. *Dis. Markers* 2013, 34, 395–405. [CrossRef] [PubMed]

26. Köhrmann, A.; Kammerer, U.; Kapp, M.; Dietl, J.; Anacker, J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. *BMC Cancer* 2009, 9, 188. [CrossRef] [PubMed]

27. Gutiérrez-Fernández, A.; Fueyo, A.; Folgueras, A.R.; Garabaya, C.; Pennington, C.J.; Pilgrim, S.; Edwards, D.R.; Holliday, D.L.; Jones, J.L.; Span, P.N.; et al. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. *Cancer Res.* 2008, 68, 2755–2763. [CrossRef]

28. McGowan, P.M.; Duffy, M.J. Matrix metalloproteinase expression and outcome in patients with breast cancer: Analysis of a published database. *Ann. Oncol.* 2008, 19, 1566–1572. [CrossRef]

29. Decock, J.; Hendrickx, W.; Drijkoningen, M.; Wildiers, H.; Neven, P.; Smeets, A.; Paridaens, R. Matrix metalloproteinase expression patterns in luminal A type breast carcinomas. *Dis. Markers* 2007, 23, 189–196. [CrossRef]

30. Duffy, M.J.; Blaser, J.; Duggan, C.; McDermott, E.; O’Higgins, N.; Fennelly, J.J.; Tschesche, H. Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. *Br. J. Cancer* 1995, 71, 1025–1028. [CrossRef] [PubMed]

31. Koskensalo, S.; Hagström, J.; Linder, N.; Lundin, M.; Sorsa, T.; Louhimo, J.; Haglund, C. Lack of MMP-9 expression is a marker for poor prognosis in Dukes’ B colorectal cancer. *BMC Clin. Pathol.* 2012, 12, 24. [CrossRef] [PubMed]

32. Väyrynen, J.P.; Vornanen, J.; Tervahartiala, T.; Sorsa, T.; Bloigu, R.; Salo, T.; Tuomisto, A.; Mäkinen, M.J. Serum MMP-8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. *Int. J. Cancer* 2012, 131, E463–E474. [CrossRef] [PubMed]

33. Verspaget, H.W.; Kubben, F.J.G.M.; Tschesche, H.; Verheijen, J.H.; Hanemaaijer, R.; Lamers, C.B.H.W. Matrix metalloproteinases increase with colorectal cancer progression. *Fibrinolysis Proteolysis* 1999, 13, 38.
34. Takeha, S.; Fujiyama, Y.; Bamba, T.; Sorsa, T.; Nagura, H.; Ohtani, H. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer. *Jpn. J. Cancer Res.* 1997, 88, 72–81. [CrossRef] [PubMed]

35. Laitinen, A.; Hagström, J.; Mustonen, H.; Kokkola, A.; Tervahartiala, T.; Sorsa, T.; Böckelman, C.; Haglund, C. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer. *Tumour Biol.* 2018, 40. [CrossRef]

36. Lin, Y.; Liu, J.; Jin, L.; Jiang, Y. Polymorphisms in matrix metalloproteinases 2, 3, and 8 increase recurrence and mortality risk by regulating enzyme activity in gastric adenocarcinoma. *Oncotarget* 2017, 8, 105971–105983. [CrossRef] [PubMed]

37. De La Peña, S.; Sampieri, C.L.; Ochoa-Lara, M.; León-Córdoba, K.; Remes-Troche, J.M. Expression of the matrix metalloproteases 2, 14, 24, and 25 and tissue inhibitor 3 as potential molecular markers in advanced human gastric cancer. *Dis. Markers* 2014, 2014, 285906. [CrossRef]

38. Kubben, F.J.; Sier, C.E.; van Duijn, W.; Griffioen, G.; Hanemaaijer, R.; van de Velde, C.J.; van Krieken, J.H.; Lamers, C.B.; Verspaget, H.W. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. *Br. J. Cancer* 2006, 94, 1035–1040. [CrossRef]

39. Åström, P.; Juurikkka, K.; Hadler-Olsen, E.S.; Svineng, G.; Cervigne, N.K.; Coletta, R.D.; Risteli, J.; Kauppila, J.H.; Skarp, S.; Kuttner, S.; et al. The interplay of matrix metalloproteinase-8, transforming growth factor-β and vascular endothelial growth factor-C cooperatively contributes to the aggressiveness of oral tongue squamous cell carcinoma. *Br. J. Cancer* 2017, 117, 1007–1016. [CrossRef]

40. Omar, A.A.; Haglund, C.; Virolainen, S.; Häyry, V.; Atula, T.; Kontio, R.; Salo, T.; Sorsa, T.; Hagström, J. MMP-7, MMP-8, and MMP-9 in oral and cutaneous squamous cell carcinomas. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol.* 2015, 119, 459–467. [CrossRef]

41. Lawal, A.; Adisa, A.; Kolude, B.; Adeyemi, B. Immunohistochemical expression of MMP-2 and MMP-8 in oral squamous cell carcinoma. *J. Clin. Exp. Dent.* 2012, 4, 19–24. [CrossRef] [PubMed]

42. Korpi, J.T.; Kervinen, V.; Mäklin, H.; Väänänen, A.; Lahtinen, M.; Läärä, E.; Ristimäki, A.; Thomas, G.; Skarp, S.; Kuttner, S.; et al. Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer. *J. Pathol. Oral.* 2012, 41, 394–399. [CrossRef] [PubMed]

43. Korampalli, T.S.; Green, V.L.; Greenman, J.; Stafford, N.D. Protein profiling of angiogenesis-related growth factorsin laryngeal carcinoma: Pattern of protein expressionin relation to tumour progression. *Int. J. Oncol.* 2011, 39, 1033–1039. [PubMed]

44. Korpi, J.T.; Kervinen, V.; Mäklin, H.; Väänänen, A.; Lahtinen, M.; Liäärä, E.; Ristimäki, A.; Thomas, G.; Ylipalosaari, M.; Åström, P.; et al. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. *Br. J. Cancer* 2008, 98, 766–775. [CrossRef] [PubMed]

45. Xie, M.; Sun, Y.; Li, Y. Expression of matrix metalloproteinases in supraglottic laryngeal cancer and its clinical implication for estimating lymph node metastases. *Laryngoscope* 2004, 114, 2243–2248. [CrossRef]

46. Kayano, K.; Shimada, T.; Shimomiya, T.; Nakai, S.; Hisa, Y.; Aoki, T.; Seiki, M.; Okada, Y. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: Possible regulation of pro-MMP-2 activation by TIMP-2. *J. Pathol.* 2004, 202, 403–411. [CrossRef]

47. Moilanen, M.; Pirilä, E.; Grönman, R.; Sorsa, T.; Salo, T. Expression and regulation of collagenase-2 (MMP-8) in head and neck squamous cell carcinomas. *J. Pathol.* 2002, 197, 72–81. [CrossRef]

48. Qin, G.; Luo, M.; Chen, J.; Dang, Y.; Chen, G.; Li, L.; Zeng, J.; Lu, Y.; Yang, J. Reciprocal activation between MMP-8 and TGF-β stimulates EMT and malignant progression of hepatocellular carcinoma. *Cancer Lett.* 2016, 374, 85–95. [CrossRef]

49. Shah, S.A.; Spinale, F.G.; Ikonomidis, J.S.; Stroud, R.E.; Chang, E.I.; Reed, C.E. Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. *J. Thorac. Cardiovasc. Surg.* 2010, 139, 984–990. [CrossRef]

50. Stadlmann, S.; Pollheimer, J.; Moser, P.L.; Raggi, A.; Amberger, A.; Margreiter, R.; Offner, F.A.; Mikuz, G.; Dirnhofer, S.; Moch, H. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. *Eur. J. Cancer* 2003, 39, 2509–2515. [CrossRef]

51. Stenman, M.; Paju, A.; Hanemaaijer, R.; Tervahartiala, T.; Leminen, A.; Stenman, U.; Konttinen, Y.T.; Sorsa, T. Collagenases (MMP-1, -8 and -13) and trypsinogen-2 in fluid from benign and malignant ovarian cysts. *Tumor Biol.* 2003, 24, 9–12. [CrossRef] [PubMed]
52. Hu, D.; Ansari, D.; Pawłowski, K.; Zhou, Q.; Sasor, A.; Welinder, C.; Kristl, T.; Bauden, M.; Rezeli, M.; Jiang, Y. Prognostic biomarkers for pancreatic ductal adenocarcinoma. Oncotarget 2018, 9, 9789–9807. [CrossRef] [PubMed]

53. Jones, L.E.; Humphreys, M.J.; Campbell, F.; Neoptolemos, J.P.; Boyd, M.T. Comprehensive Analysis of Matrix Metalloproteinase and Tissue Inhibitor Expression in Pancreatic Cancer: Increased Expression of Matrix Metalloproteinase-7 Predicts Poor Survival. Clin. Cancer Res. 2004, 10, 2832–2845. [CrossRef] [PubMed]

54. Ciążyńska, M.; Bednarski, I.A.; Wóźd, K.; Kolano, P.; Narbut, J.; Sobjanek, M.; Wozniacka, A.; Lesiak, A. Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with normal skin. J. Cutan. Pathol. 2009, 36, 657–665. [CrossRef] [PubMed]

55. Kuivanen, T.T.; Jeskanen, L.; Kyllönen, L.; Impola, U.; Saarialho-Kere, U.K. Expression of matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas. Mod. Pathol. 2006, 19, 1203–1212. [CrossRef] [PubMed]

56. Impola, U.; Jeskanen, L.; Ravanti, L.; Syrjänen, S.; Baldursson, B.; Kähäri, V.M.; Saarialho-Kere, U. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br. J. Dermatol. 2005, 152, 720–726. [CrossRef] [PubMed]

57. Giambernardi, T.A.; Sakaguchi, A.Y.; Gluhak, J.; Pavlin, D.; Troyer, D.A.; Das, G.; Rodeck, U.; Klebe, R.J. Neutrophil collagenase (MMP-8) is expressed during early development in neural crest cells as well as in adult melanoma cells. Matrix Biol. 2001, 20, 577–587. [CrossRef]

58. Varani, J.; Hattori, Y.; Chi, Y.; Schmidt, T.; Perone, P.; Zeigler, M.E.; Fader, D.J.; Johnson, T.M. Collagenolytic and gelatinolytic matrix metalloproteinases and their inhibitors in basal cell carcinoma of skin: Comparison with normal skin. Br. J. Cancer 2000, 82, 657–665. [CrossRef]

59. Roebuck, M.M.; Hellwell, T.R.; Chaudhry, I.H.; Kalogrianitis, S.; Carter, S.; Kemp, G.J.; Ritchie, D.A.; Jane, M.J.; Frostick, S.P. Matrix metalloproteinase expression is related to angiogenesis and histologic grade in spindle cell soft tissue neoplasms of the extremities. Am. J. Clin. Pathol. 2005, 123, 405–414. [CrossRef]

60. Kebebew, E.; Meng, P.; Reiff, E.; Duh, Q.; Clark, O.H.; McMillan, A. ECM1 and TIMPSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann. Surg. 2005, 242, 353–363. [CrossRef]

61. Ueno, H.; Yamashita, K.; Azumano, I.; Inoue, M.; Okada, Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int. J. Cancer 1999, 84, 470–477. [CrossRef]

62. Sarper, M.; Allen, M.D.; Gomm, J.; Haywood, L.; Decock, J.; Thirkettle, S.; Ustaoglu, A.; Sarker, S.J.; Marshall, J.; Edwards, D.R.; et al. Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. Breast Cancer Res. 2017, 19, 33. [CrossRef] [PubMed]

63. Duffy, M.J.; Duggan, C.; Maguire, T.; Mulcahy, K.; Elvin, P.; McDermott, E.; Fennelly, J.J.; O’Higgins, N. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzym. Protein 1996, 49, 85–93. [CrossRef]

64. Kuivanen, T.; Jeskanen, L.; Kyllönen, L.; Isaka, K.; Saarialho-Kere, U. Matrix metalloproteinase-26 is present more frequently in squamous cell carcinomas of immunosuppressed compared with immunocompetent patients. J. Cutan. Pathol. 2009, 36, 929–936. [CrossRef] [PubMed]

65. Hardt, M.; Lam, D.K.; Dolan, J.C.; Schmidt, B.L. Surveying proteolytic processes in human cancer microenvironments by microdialysis and activity-based mass spectrometry. Proteom. Clin. Appl. 2011, 5, 636–643. [CrossRef] [PubMed]

66. Ilmarinen, T.; Lont, T.; Hagström, J.; Tervahartiala, T.; Sorsa, T.; Haglund, C.; Munck-Wickland, E.; Ramqvist, T.; Dalianis, T.; Aaltoenen, L.M. Systemic matrix metalloproteinase-8 response in chronic tonsillitis. Infect. Dis. 2017, 49, 302–307. [CrossRef] [PubMed]

67. Wahlgren, J.; Maisi, P.; Sorsa, T.; Sutinen, M.; Tervahartiala, T.; Pirilä, E.; Teronen, O.; Hietanen, J.; Tjäderhane, L.; Salo, T. Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions. J. Pathol. 2001, 194, 217–224. [CrossRef] [PubMed]

68. Kim, J.; Kim, T.; Jang, J.; Jang, Y.; Lee, K.; Lee, S. Analysis of matrix metalloproteinase mRNAs expressed in hepatocellular carcinoma cell lines. Mol. Cells 2001, 12, 32–40. [CrossRef]

69. Merkerova, M.; Klamova, H.; Brdicka, R.; Bruchova, H. Targeting of gene expression by siRNA in CML primary cells. Mol. Biol. Rep. 2007, 34, 27–33. [CrossRef]
70. Linkov, F.; Gu, Y.; Arslan, A.A.; Liu, M.; Shore, R.E.; Velikokhatnaya, L.; Koenig, K.L.; Tonio, P.; Marrango, A.; Yurkovetsky, Z.; et al. Reliability of tumor markers, chemokines, and metastasis-related molecules in serum. *Eur. Cytokine Netw.* 2009, 20, 21–26. [CrossRef] [PubMed]

71. Lempinen, M.; Lyytinen, I.; Nordin, A.; Tervahartiala, T.; Mäkisalo, H.; Sorsa, T.; Isoniemi, H. Prognostic value of plasma MMP-8 and TIMP-1 in patients with ulceration and vascular invasion of malignant melanoma. *Br. J. Cancer* 2010, 107, 2221–2227. [CrossRef] [PubMed]

72. Tong, Q.; Wang, X.L.; Li, S.B.; Yang, G.L.; Jin, S.; Gao, Z.Y.; Liu, X.B. Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: A preliminary study based on the screening of serum markers using protein chips. *OncoTargets Ther.* 2018, 11, 5777–5787. [CrossRef] [PubMed]

73. Pradhan-Palikhe, P.; Vesterinen, T.; Tarkkanen, J.; Leivo, I.; Sorsa, T.; Salo, T.; Risteli, J. Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma. *Oral Oncol.* 2012, 48, 136–140. [CrossRef]

74. Serra, R.; Grande, R.; Gallelli, L.; Rende, P.; Scarcella, E.; Buffone, G.; Caliò, F.G.; Gasbarro, V.; Amato, B.; de Franciscis, S. Carotid body paragangliomas and matrix metalloproteinases. *Ann. Vasc. Surg.* 2014, 28, 1665–1670. [CrossRef] [PubMed]

75. Park, H.D.; Kang, E.S.; Kim, J.W.; Lee, K.T.; Lee, K.H.; Park, Y.S.; Park, J.O.; Lee, J.; Heo, J.S.; Choi, S.H.; et al. Plasma CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. *Proteomics* 2012, 12, 3590–3597. [CrossRef]

76. Komorowski, J.; Pasieka, Z.; Jankiewicz-Wika, J.; Stepien, H. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. *Thyroid* 2002, 12, 655–662. [CrossRef]

77. Svetak, R.S.; Shah, J.B.; Xing, J.; Chang, D.; Lin, J.; McConkey, D.J.; Wu, X.; Dinney, C.P. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. *Cancer* 2010, 116, 4513–4519. [CrossRef]
88. Marin-Aguilera, M.; Reig, Ò.; Lozano, J.J.; Jiménez, N.; Garcia-Recio, S.; Erill, N.; Gaba, L.; Tagliapietra, A.; Ortega, V.; Carrera, G.; et al. Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. *Oncotarget* 2015, 6, 10604–10616. [CrossRef]

89. Reichenberger, F.; Eickelberg, O.; Wyser, C.; Perruchoud, A.P.; Roth, M.; Tamm, M. Distinct endobronchial expression of matrix-metalloproteinases (MMP) and their endogenous inhibitors in lung cancer. *Swiss Med. Wkly.* 2001, 131, 273–279.

90. Tsai, T.H.; Wang, Y.M.; Chang, W.S.; Tsai, C.W.; Wu, H.C.; Hsu, H.M.; Wang, Y.C.; Li, H.T.; Gong, C.L.; Bau, D.T.; et al. Association of Matrix Metalloproteinase-8 Genotypes with the Risk of Bladder Cancer. *Anticancer Res.* 2018, 38, 5159–5164. [CrossRef]

91. Srivastava, P.; Kapoor, R.; Mittal, R.D. Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. *Urol. Oncol. Semin. Orig. Invest.* 2013, 31, 247–254. [CrossRef] [PubMed]

92. Kader, A.K.; Liu, J.; Shao, L.; Dinney, C.P.; Lin, J.; Wang, Y.; Gu, J.; Grossman, H.B.; Wu, X. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. *Clin. Cancer Res.* 2007, 13, 2614–2620. [CrossRef] [PubMed]

93. Kader, A.K.; Shao, L.; Dinney, C.P.; Schabath, M.B.; Wang, Y.; Liu, J.; Gu, J.; Grossman, H.B.; Wu, X. Matrix metalloproteinase polymorphisms and bladder cancer risk. *Cancer Res.* 2006, 66, 11644–11648. [CrossRef] [PubMed]

94. Hsiao, C.L.; Liu, L.C.; Shih, T.C.; Chuang, C.L.; Chen, G.L.; Wang, H.C.; Pan, S.Y.; Shen, T.C.; Tsai, C.W.; Chang, W.S.; et al. The Association of Matrix Metalloproteinase-8 Promoter Genotypes in Breast Cancer. *Anticancer Res.* 2018, 38, 2181–2185. [PubMed]

95. Beeghly-Fadiel, A.; Zheng, W.; Lu, W.; Long, J.; Zheng, Y.; Cai, H.; Gu, K.; Chen, Z.; Cai, Q.; Gao, Y.T.; et al. Replication study for reported SNP associations with breast cancer survival. *J. Cancer Res. Clin. Oncol.* 2012, 138, 1019–1026. [CrossRef] [PubMed]

96. Debnak, T.; Jakubowska, A.; Serrano-Fernández, P.; Kurzawski, G.; Cybulski, C.; Chauhan, S.R.; Laxton, R.C.; Maleszka, R.; Lubinski, J.; Ye, S. Association of MMP8 gene variation with an increased risk of malignant melanoma. *Melanoma Res.* 2011, 21, 464–468. [CrossRef] [PubMed]

97. Mavaddat, N.; Dunning, A.M.; Ponder, B.A.J.; Easton, D.F.; Pharoah, P.D. Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. *Cancer Epidemiol. Biomark. Prev.* 2009, 18, 255–259. [CrossRef] [PubMed]

98. Decock, J.; Long, J.R.; Laxton, R.C.; Shu, X.O.; Hodgkinson, C.; Hendrickx, W.; Pearce, E.G.; Gao, Y.T.; Pereira, A.C.; Paridaens, R.; et al. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. *Cancer Res.* 2007, 67, 10214–10221. [CrossRef] [PubMed]

99. Kubben, F.J.; Sier, C.F.; Meijer, M.J.; van Den Berg, M.; van der Reijden, J.J.; Griffioen, G.; van de Velde, C.J.; Lamers, C.B.; Verspaget, H.W. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. *Br. J. Cancer* 2006, 95, 744–751. [CrossRef] [PubMed]

100. Hung, Y.W.; Tsai, C.W.; Wu, C.N.; Shih, L.C.; Chen, Y.Y.; Liu, Y.F.; Hung, H.S.; Shen, M.Y.; Chang, W.S.; Bau, D.T. The Contribution of Matrix Metalloproteinase-8 Promoter Polymorphism to Oral Cancer Susceptibility. *In Vivo* 2017, 31, 585–590.

101. Liu, H.; Huang, P.Y.; Tang, L.Q.; Chen, Q.Y.; Zhang, Y.; Zhang, L.; Guo, L.; Luo, D.H.; Mo, H.Y.; Xiang, Y.Q.; et al. Functional polymorphisms of matrix metalloproteinase-9 and survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. *Med. Oncol.* 2013, 30, 685. [CrossRef] [PubMed]

102. Pei, J.S.; Chang, W.S.; Hsu, P.C.; Hung, Y.W.; Cheng, S.P.; Tsai, C.W.; Bau, D.T.; Gong, C.L. The Contribution of MMP-8 Promoter Genotypes to Childhood Leukemia. *In Vivo* 2017, 31, 1059–1064. [PubMed]

103. Qiu, W.; Zhou, G.; Zhai, Y.; Zhang, X.; Xie, W.; Zhang, H.; Yang, H.; Zhi, L.; Yuan, X.; Zhang, X.; et al. No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population. *Cancer Epidemiol. Biomark. Prev.* 2008, 17, 2514–2518. [CrossRef] [PubMed]

104. Shen, T.C.; Hsia, T.C.; Chao, C.Y.; Chen, W.C.; Chen, C.Y.; Chen, W.C.; Lin, Y.T.; Hsiao, C.L.; Chang, W.S.; Tsai, C.W.; et al. The Contribution of MMP-8 Promoter Polymorphisms in Lung Cancer. *Anticancer Res.* 2017, 37, 3563–3567. [PubMed]
105. González-Arriaga, P.; López-Cima, M.F.; Fernández-Somoano, A.; Pascual, T.; Marrón, M.G.; Puente, X.S.; Tardón, A. Polymorphism +17 C/G in Matrix Metalloproteinase MMP8 decreases lung cancer risk. *BMC Cancer* 2008, 8, 378. [CrossRef] [PubMed]

106. Wang, Y.; Ye, Y.; Lin, J.; Meyer, L.; Wu, X.; Lu, K.; Liang, D. Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome. *Mol. Carcinog.* 2015, 54, 430–439. [CrossRef]

107. Arechavaleta-Velasco, F.; Cuevas-Antonio, R.; Dominguez-Lopez, P.; Estrada-Moscoso, I.; Imani-Razavi, F.S.; Zemerino-Toquero, M.; Díaz-Cueto, L. Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer. *Med. Oncol.* 2014, 31, 132. [CrossRef]

108. Qiu, Z.; Hu, J.; Xu, H.; Wang, W.; Nie, C.; Wang, X. Generation of antitumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment. *Anti-Cancer Drugs* 2013, 24, 677–689. [CrossRef]

109. Murugan, A.K.; Dong, J.; Xie, J.; Xing, M. Uncommon gnaq, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. *Endocr. Pathol.* 2011, 22, 97–102. [CrossRef]

110. McLaughlin, J.; Rella, J.; Bakan, A.; Kong, L.; Zhu, L.; Frederick, D.; Ferrell, R.; Bahar, I.; Shapiro, S.; et al. Impact of pro-domain stability of matrix metalloproteinase-8 on the outcome of sepsis. *Critical Care* 2011, 15, P278. [CrossRef]

111. Nan, H.; Niu, T.; Hunter, D.J.; Han, J. Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk. *Cancer Epidemiol. Biomark. Prev.* 2008, 17, 3551–3557. [CrossRef] [PubMed]

112. Palavalli, L.H.; Prickett, T.D.; Wunderlich, J.R.; Wei, X.; Burrell, A.S.; Porter-Gill, P.; Davis, S.; Wang, C.; Cronin, J.C.; Agrawal, N.S.; et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. *Nat. Genet.* 2009, 41, 518–520. [CrossRef] [PubMed]

113. Chernov, A.V.; Baranovskaya, S.; Golubkov, V.S.; Wakeman, D.R.; Snyder, E.Y.; Williams, R.; Strongin, A.Y. Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. *J. Biol. Chem.* 2010, 285, 19647–19659. [CrossRef] [PubMed]

114. Jin, H.; Wang, W. MicroRNA-539 suppresses osteosarcoma cell invasion and migration in vitro and targeting Matrix metallopeptidase-8. *Int. J. Clin. Exp. Pathol.* 2015, 8, 8075–8082. [PubMed]

115. GIRIEZ, O.; LAUER, J.L.; FIELDS, G.B. Comparison of matrix metalloproteinase protein and activity profiling. *Anal. Biochem.* 2011, 409, 37–45. [CrossRef] [PubMed]

116. Bachmeier, B.E.; Nerlich, A.G.; Boukamp, P.; Lichtinghagen, R.; Tschesche, H.; Fritz, H.; Fink, E. Human keratinocyte cell lines differ in the expression of the collagenolytic matrix metalloproteinases-1,-8, and -13 and of TIMP-1. *Biol. Chem.* 2000, 381, 509–516. [PubMed]

117. Balbin, M.; Fueyo, A.; Tester, A.M.; Pendás, A.M.; Pittiot, A.S.; Astudillo, A.; Overall, C.M.; Shapiro, S.D.; López-Otín, C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. *Nat. Genet.* 2003, 35, 252–257. [CrossRef]

118. Kotula, E.; Berthault, N.; Agrario, C.; Lienafa, M.C.; Simon, A.; Dingli, F.; Loew, D.; Sibut, V.; Saule, S.; Dutreix, M. DNA-PKcs plays role in cancer metastasis through regulation of secreted proteins involved in migration and invasion. *Cell Cycle* 2009, 14, 1961–1972. [CrossRef]

119. Van Deventer, H.W.; Wu, Q.P.; Bergstrahl, D.T.; Davis, B.K.; O’Connor, B.P.; Ting, J.P.; Serody, J.S. C-C chemokine receptor 5 on pulmonary fibrocytes facilitates migration and promotes metastasis via matrix metalloproteinase 9. *Am. J. Pathol.* 2008, 173, 253–264. [CrossRef]

120. Bachmeier, B.E.; Nerlich, A.G.; Lichtinghagen, R.; Sommerhoff, C.P. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. *Anticancer Res.* 2001, 21, 3821–3828.

121. Bachmeier, B.E.; Albini, A.; Vené, R.; Benelli, R.; Noonan, D.; Weigert, C.; Weiler, C.; Lichtinghagen, R.; Jochum, M.; Nerlich, A.G. Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. *Exp. Cell Res.* 2005, 305, 83–98. [CrossRef] [PubMed]

122. Bartsch, J.E.; Staren, E.D.; Appert, H.E. Matrix metalloproteinase expression in breast cancer. *J. Surg. Res.* 2003, 110, 383–392. [CrossRef]

123. Thirkettle, S.; Decock, J.; Arnold, H.; Pennington, C.J.; Jaworski, D.M.; Edwards, D.R. Matrix metalloproteinase 8 (collagenase 2) induces the expression of interleukins 6 and 8 in breast cancer cells. *J. Biol. Chem.* 2013, 288, 16282–16294. [CrossRef] [PubMed]
124. Agarwal, D.; Goodison, S.; Nicholson, B.; Tarin, D.; Urquidi, V. Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. *Differentiation* 2003, 71, 114–125. [CrossRef] [PubMed]

125. Stark, A.M.; Anuszkiewicz, B.; Mentlein, R.; Yoneda, T.; Mehdorn, H.M.; Held-Feindt, J. Differential expression of matrix metalloproteinases in brain- and bone-seeking clones of metastatic MDA-MB-231 breast cancer cells. *J. Neuro-Oncol.* 2007, 81, 39–48. [CrossRef] [PubMed]

126. Koellensperger, E.; Bonnert, L.C.; Zoernig, I.; Marmé, F.; Sandmann, S.; Germann, G.; Gramley, F.; Leimer, U. The impact of human adipose tissue-derived stem cells on breast cancer cells: Implications for cell-assisted lipotransfers in breast reconstruction. *Stem Cell Res. Ther.* 2017, 8, 121. [CrossRef]

127. Montel, V.; Kleeman, J.; Agarwal, D.; Spinella, D.; Kawai, K.; Tarin, D. Altered Metastatic Behavior of Human Breast Cancer Cells after Experimental Manipulation of Matrix Metalloproteinase 8 Gene Expression. *Cancer Res.* 2004, 64, 1687–1694. [CrossRef]

128. Decock, J.; Hendricks, W.; Thirkettle, S.; Gutiérrez-Fernández, A.; Robinson, S.D.; Edwards, D.R. Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice. *Breast Cancer Res.* 2015, 17, 38. [CrossRef]

129. Soria-Valles, C.; Gutiérrez-Fernández, A.; Guti, M.; Mari, B.; Fuego, A.; Gomis, R.R.; López-Otín, C. The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21. *Oncogene* 2014, 33, 3054–3063. [CrossRef]

130. Merrell, M.A.; Ilvesaro, J.M.; Lehtonen, N.; Sorsa, T.; Gehrs, B.; Rosenthal, E.; Chen, D.; Shackley, B.; Harris, K.W.; Selander, K.S. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. *Mol. Cancer Res.* 2006, 4, 437–447. [CrossRef] [PubMed]

131. Binder, C.; Hagemann, T.; Husen, B.; Schulz, M.; Einspanier, A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. *Mol. Hum. Reprod.* 2002, 8, 789–796. [CrossRef] [PubMed]

132. Spiegel, A.; Brooks, M.W.; Houshyar, S.; Reinhardt, F.; Ardolino, M.; Fessler, E.; Chen, M.B.; Krall, J.A.; DeCock, J.; Zervantonakis, I.K.; et al. Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. *Cancer Discov.* 2016, 6, 630–649. [CrossRef] [PubMed]

133. Sabeh, F.; Ota, I.; Holmbeck, K.; Birkedal-Hansen, H.; Soloway, P.; Balbin, M.; Lopez-Otín, C.; Shapiro, S.; Inada, M.; Krane, S.; et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. *J. Cell Biol.* 2004, 167, 769–781. [CrossRef] [PubMed]

134. Ramanujum, R.; Lin, Y.; Liu, J.; He, S. Regulatory expression of MMP-8/MMP-9 and inhibition of proliferation, migration and invasion in human lung cancer A549 cells in the presence of HGF variants. *Kaohsiung J. Med. Sci.* 2013, 29, 530–539. [CrossRef] [PubMed]

135. Saito, R.; Miki, Y.; Ishida, N.; Inoue, C.; Kobayashi, M.; Hata, S.; Yamada-Okabe, H.; Okada, Y.; Sasano, H. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting. *Int. J. Mol. Sci.* 2018, 19, 609. [CrossRef] [PubMed]

136. Pellinen, T.; Rantala, J.K.; Arjonen, A.; Mpindi, J.; Kallioniemi, O.; Ivaska, J. A functional genetic screen reveals new regulators of β1-integrin activity. *J. Cell Sci.* 2012, 125, 649–661. [CrossRef] [PubMed]

137. Ylipalosaari, M.; Thomas, G.J.; Nystrom, M.; Salhimi, S.; Marshall, J.F.; Huotari, V.; Tervahartiala, T.; Sorsa, T.; Salo, T. αβδ6 integrin down-regulates the MMP-13 expression in oral squamous cell carcinoma cells. *Exp. Cell Res.* 2005, 309, 273–283. [CrossRef] [PubMed]

138. Kuijper, S.; Turner, C.J.; Adams, R.H. Regulation of Angiogenesis by Eph-Ephrin Interactions. *Trends Cardiovasc. Med.* 2007, 17, 145–151. [CrossRef]

139. Tanaka, M.; Sasaki, K.; Kamata, R.; Sakai, R. The C-terminus of ephrin-B1 regulates metalloproteinase secretion and invasion of cancer cells. *J. Cell Sci.* 2007, 120, 2179–2189. [CrossRef]

140. Tanaka, M.; Kamata, R.; Yanagihara, K.; Sakai, R. Suppression of gastric cancer dissemination by ephrin-B1-derived peptide. *Cancer Sci.* 2010, 101, 87–93. [CrossRef]

141. Pirilä, E.; Sharabi, A.; Salo, T.; Quaranta, V.; Tu, H.; Heljasvaara, R.; Koshikawa, N.; Sorsa, T.; Maisi, P. Matrix metalloproteinases process the laminin-5 γ2 chain and regulate epithelial cell migration. *Biochem. Biophys. Res. Commun.* 2003, 303, 1012–1017. [CrossRef]
142. Van Valckenborgh, E.; Croucher, P.I.; de Raeve, H.; Carron, C.; de Leenheer, E.; Blacher, S.; Devy, L.; Noël, A.; De Bruyne, E.; Asosingh, K.; et al. Multifunctional role of matrix metalloproteinases in multiple myeloma: A study in the 5T2MM mouse model. *Am. J. Pathol.* 2004, 165, 869–878. [CrossRef]

143. Hsieh, C.H.; Hsiung, S.C.; Yeh, C.T.; Yen, C.F.; Chou, Y.H.; Lei, W.Y.; Pang, S.T.; Chuang, C.K.; Liao, S.K. Differential expression of CD44 and CD24 markers discriminates the epitheloid from the fibroblastoid subset in a sarcomatoid renal carcinoma cell line. Evidence suggesting the existence of cancer stem cells in both subsets as studied with sorted cells. *Oncotarget* 2017, 8, 15593–15609. [CrossRef] [PubMed]

144. Kwon, C.H.; Park, H.J.; Lee, J.R.; Kim, H.K.; Jeon, T.Y.; Jo, H.J.; Kim, D.H.; Kim, G.H.; Park, D.Y. Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer. *Br. J. Cancer* 2014, 111, 1993–2002. [CrossRef] [PubMed]

145. Johnson, E.L.; Singh, R.; Singh, S.; Johnson-Holiday, C.M.; Grizzle, W.E.; Partridge, E.E.; Lillard, J.W. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. *World J. Surg. Oncol.* 2010, 8, 62. [CrossRef] [PubMed]

146. Singh, S.; Singh, U.P.; Stiles, J.K.; Grizzle, W.E.; Lillard, J.W., Jr. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. *Clin. Cancer Res.* 2004, 10, 8743–8750. [CrossRef] [PubMed]

147. Liu, S.; Liu, Y.; Huang, W.; Huang, G.; Chen, T.; Lin, M. Up-regulation of matrix metalloproteinase-8 by betel quid extract and arecoline and its role in 2D motility. *Oral Oncol.* 2007, 43, 1026–1033. [CrossRef] [PubMed]

148. Moilanen, M.; Sorsa, T.; Stenman, U.H.; Nyberg, P.; Lindy, O.; Vesterinen, J.; Paju, A.; Konttinen, Y.T.; Stenman, U.H.; Salo, T. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. *Biochemistry* 2003, 42, 5414–5420. [CrossRef] [PubMed]

149. Nyberg, P.; Heikkilä, P.; Sorsa, T.; Luostarinen, J.; Heljasvaara, R.; Stenman, U.H.; Pihlajaniemi, T.; Salo, T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloproteinase-2, -9, and -13. *J. Biol. Chem.* 2003, 278, 22404–22411. [CrossRef] [PubMed]

150. Furukawa, A.; Tsuji, M.; Nishitani, M.; Kanda, K.; Inoue, Y.; Kanayama, H.O.; Kagawa, S. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency. *Urology* 1998, 51, 849–853. [CrossRef]

151. Scotlandi, K.; Benini, S.; Manara, M.C.; Serra, M.; Nanni, P.; Lollini, P.L.; Nicoletti, G.; Landuzzi, L.; Chano, T.; Picci, P. Murine model for skeletal metastases of Ewing’s sarcoma. *J. Orthop. Res.* 2000, 18, 959–966. [CrossRef] [PubMed]

152. Jiang, X.; Dutton, C.M.; Qi, W.N.; Block, J.A.; Brodt, P.; Durko, M.; Scully, S.P. Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma. *J. Orthop. Res.* 2003, 21, 1063–1070. [CrossRef]

153. Bialek, J.; Kunanuvat, U.; Hombach-Klonisch, S.; Spens, A.; Stetefeld, J.; Sunley, K.; Lippert, D.; Wilkins, J.A.; Hoang-Vu, C.; Klonisch, T. Relaxin enhances the collagenolytic activity and in vitro invasiveness by upregulating matrix metalloproteinases in human thyroid carcinoma cells. *Mol. Cancer Res.* 2011, 9, 673–887. [CrossRef] [PubMed]

154. Tjomsland, V.; Pomicianowska, E.; Aastrum, M.; Sandnes, D.; Verbeke, C.S.; Gladhaug, I.P. Profile of MMP and TIMP Expression in Human Pancreatic Stellate Cells: Regulation by IL-1Î± and TGFÎ² and Implications for Migration of Pancreatic Cancer Cells. *Neoplasia* 2016, 18, 447–456. [CrossRef] [PubMed]

155. Kominsky, S.L.; Doucet, M.; Thorpe, M.; Weber, K.L. MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-Î²1. *Clin. Exp. Metastasis* 2008, 25, 865–870. [CrossRef] [PubMed]

156. Partridge, J.J.; Madsen, M.A.; Ardi, V.C.; Papagiannakopoulos, T.; Kupriyanova, T.A.; Quigley, J.P.; Deryugina, E.I. Functional analysis of matrix metalloproteinases and tissue inhibitors of metalloproteinases differentially expressed by variants of human HT-1080 fibrosarcoma exhibiting high and low levels of invrasvation and metastasis. *J. Biol. Chem.* 2007, 282, 35964–35977. [CrossRef] [PubMed]

157. Cheng, J.; Sauthoff, H.; Huang, Y.; Kutler, D.J.; Bajwa, S.; Rom, W.N.; Hay, J.G. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. *Mol. Ther.* 2007, 15, 1982–1990. [CrossRef] [PubMed]

158. Mok, W.; Boucher, Y.; Jain, R.K. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. *Cancer Res.* 2007, 67, 10664–10668. [CrossRef] [PubMed]
19. Zheng, X.; Goins, B.A.; Cameron, I.L.; Santoyo, C.; Bao, A.; Frohlich, V.C.; Fullerton, G.D. Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts. Cancer Chemother. Pharmacol. 2011, 67, 173–182. [CrossRef] [PubMed]

160. Ke, S.; Wang, W.; Qiu, X.; Zhang, F.; Tyuustej, I.; Cameron, A.G.; Zhang, S.; Yu, D.; Zou, C.; Gao, X.; et al. Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice. Curr. Mol. Med. 2013, 13, 446–458. [PubMed]

161. Kim, M.H.; Gutierrez, A.M.; Goldfarb, R.H. Different mechanisms of soy isoflavones in cell cycle regulation and inhibition of invasion. Anticancer Res. 2002, 22, 3811–3817. [PubMed]

162. Kim, M.H.; Albertsson, P.; Xue, Y.; Nannmark, U.; Kitson, R.P.; Goldfarb, R.H. Expression of neutrophil collagenase (MMP-8) in Jurkat T leukemia cells and its role in invasion. Anticancer Res. 2001, 21, 45–50. [PubMed]

163. Kim, B.R.; Jeon, Y.K.; Nam, M.J. A mechanism of apigenin-induced apoptosis is potentially related to anti-angiogenesis and anti-migration in human hepatocellular carcinoma cells. Food Chem. Toxicol. 2011, 49, 1626–1632. [CrossRef] [PubMed]

164. Man, S.; Chai, H.; Cui, J.; Yao, J.; Ma, L.; Gao, W. Antitumor and anti-metastatic mechanisms of Rhizoma paridis saponins in Lewis mice. Environ. Toxicol. 2018, 33, 149–155. [CrossRef] [PubMed]

165. Arviso, R.R.; Saha, S.; Wang, E.; Robertson, J.D.; Bhattacharya, R.; Mukherjee, P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc. Natl. Acad. Sci. USA 2013, 110, 6700–6705. [CrossRef]

166. Musrati, A.A.; Tervahartiala, T.; Gürsoy, M.; Könönen, E.; Fteita, D.; Sorsa, T.; Uitto, V.J.; Gürsoy, U.K. Human neutrophil peptide-1 affects matrix metalloproteinase-2, -8 and -9 secretions of oral squamous cell carcinoma cell lines in vitro. Arch. Oral Biol. 2016, 66, 1–7. [CrossRef] [PubMed]

167. Etminan, N.; Peters, C.; Ficnar, J.; Anласik, S.; Bünemann, E.; Slotty, P.; Hänggi, D.; Steiger, H.J.; Sorg, R.V.; Stummer, W. Modulation of migratory activity and invasiveness of human glioma spheroids following 5-aminolevulinic acid-based photodynamic treatment. J. Neurosurg. 2011, 115, 281–288. [CrossRef] [PubMed]

168. De Franciscis, S.; Grande, R.; Buttrico, L.; Buffone, G.; Gallelli, L.; Scarcello, E.; Calio, F.G.; de Vito, D.; Compagna, R.; Amato, M.; et al. Resection of carotid body tumors reduces arterial blood pressure. An underestimated neuroendocrine syndrome. Int. J. Surg. 2014, 12, 63–67. [CrossRef] [PubMed]

169. Finke, J.; Ko, J.; Rini, B.; Rayman, P.; Ireland, J.; Cohen, P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 2011, 11, 853–858. [CrossRef] [PubMed]

170. Shinnoh, M.; Horinaka, M.; Yasaki, T.; Yoshikawa, S.; Morita, M.; Yamada, T.; Miki, T.; Sakai, T. Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8. Int. J. Oncol. 2013, 42, 903–911. [CrossRef]

171. Reel, B.; Korkmaz, C.G.; Arun, M.Z.; Yildirim, G.; Ogut, D.; Kaymak, A.; Micili, S.; Ergur, B.U. The Regulation of Matrix Metalloproteinase Expression and the Role of Discoidin Domain Receptor 1/2 Signalling in Zoledronate-treated PC3 Cells. J. Cancer 2015, 6, 1020–1029. [CrossRef] [PubMed]

172. Xu, Q.; Ohara, N.; Liu, J.; Amano, M.; Sitruk-Ware, R.; Yoshiida, S.; Maruo, T. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol. Hum. Reprod. 2008, 14, 181–191. [CrossRef] [PubMed]

173. Boyd, S.; Tolvanen, K.; Virolainen, S.; Kuivanen, T.; Kyllönen, L.; Saarialho-Kere, U. Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immuno-suppressed patients and controls. Virchows Arch. 2008, 452, 83–90. [CrossRef] [PubMed]

174. Vihinen, P.; Tervahartiala, T.; Sorsa, T.; Hansson, J.; Bastholt, L.; Aamdal, S.; Stierner, U.; Pyrhönen, S.; Syrjänen, K.; et al. Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels. Cancer Immunol. Immunother. 2014, 63, 173–180. [CrossRef] [PubMed]

175. Van Roy, M.; van Lint, P.; van Laere, I.; Wielockx, B.; Wilson, C.; López-Otín, C.; Shapiro, S.; Libert, C. Involvement of specific matrix metalloproteinases during tumor necrosis factor/IFNγ-based cancer therapy in mice. Mol. Cancer Ther. 2007, 6, 2563–2571. [CrossRef] [PubMed]

176. Lin, C.; Wu, C.; Huang, S.; Wu, L.S. Polymorphisms of matrix metalloproteinases and their association with metastasis and the efficacy of androgen-deprivation therapy for prostate cancer in Taiwanese men. Urol. Sci. 2015, 26, 259–266. [CrossRef]

177. Jehmlich, N.; Stegmaier, P.; Golatowski, C.; Salazar, M.G.; Rischke, C.; Henke, M.; Völker, U. Differences in the whole saliva baseline proteome profile associated with development of oral mucositis in head and neck cancer patients undergoing radiotherapy. J. Proteom. 2015, 125, 98–103. [CrossRef]
178. Pasternak, B.; Matthiessen, P.; Jansson, K.; Andersson, M.; Aspenberg, P. Elevated intraperitoneal matrix metalloproteinases-8 and -9 in patients who develop anastomotic leakage after rectal cancer surgery: A pilot study. *Colorectal Dis. 2010, 12*, e93–e98. [CrossRef]
179. Davies, B.; Brown, P.D.; East, N.; Crimmin, M.J.; Barkwill, F.R. A Synthetic Matrix Metalloproteinase Inhibitor Decreases Tumor Burden and Prolongs Survival of Mice Bearing Human Ovarian Carcinoma Xenografts. *Cancer Res. 1993*, 53, 2087.
180. Levitt, N.C.; Eskens, F.A.; O’Byrne, K.J.; Propper, D.J.; Denis, L.J.; Owen, S.J.; Choi, L.; Foekens, J.A.; Wilner, S.; Wood, J.M.; et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. *Clin. Cancer Res. 2001*, 7, 1912–1922.
181. Dive, V.; Andarawewa, K.L.; Boulay, A.; Matziari, M.; Beau, F.; Guerin, E.; Rousseau, B.; Yiotakis, A.; Pasternak, B.; Matthiessen, P.; Jansson, K.; Andersson, M.; Aspenberg, P. Elevated intraperitoneal matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. *ChembMedChem 2011*, 46, 1258–1268. [CrossRef] [PubMed]
182. Scoffafava, A.; Supuran, C. Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, and N-Hydroxysulfonamides Inhibit Both These Zinc Enzymes. *J. Med. Chem. 2000*, 43, 3677–3687. [CrossRef] [PubMed]
183. Teronen, O.; Heikkilä, P.; Konttinen, Y.T.; Laitinen, M.; Salo, T.; Hanemaaijer, R.; Teronen, A.; Maisi, P.; Sorsa, T. MMP Inhibition and Downregulation by Bisphosphonates. *Ann. NY Acad. Sci. 1999*, 878, 453–465. [CrossRef] [PubMed]
184. Becker, D.P.; Villamil, C.I.; Barta, T.E.; Bedell, L.J.; Boehm, T.L.; DeCrescenzo, G.A.; Freskos, J.N.; Getman, D.P.; Hockerman, S.; Heintz, R.; et al. Synthesis and structure-activity relationships of β- and α-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy. *J. Med. Chem. 2005*, 48, 6713–6730. [CrossRef] [PubMed]
185. Reich, R.; Katz, Y.; Hadar, Y.; Breuer, E. Carbamoylphosphonate matrix metalloproteinase inhibitors 3: In vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis. *Clin. Cancer Res. 2005*, 11, 3925–3929. [CrossRef] [PubMed]
186. Breuer, E.; Salomon, C.J.; Katz, Y.; Chen, W.; Lu, S.; Rüschtenthaler, G.V.; Hadar, R.; Reich, R. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. *J. Med. Chem. 2004*, 47, 2826–2832. [CrossRef]
187. Rubino, M.T.; Agamennone, M.; Campestrè, C.; Campiglia, P.; Cremasco, V.; Faccio, R.; Laghezza, A.; Loidice, F.; Maggi, D.; Panza, E.; et al. Biphenyl Sulfonylamino Methyl Bisphosphonic Acids as Inhibitors of Matrix Metalloproteinases and Bone Resorption. *ChemMedChem 2011*, 6, 1258–1268. [CrossRef]
188. Matziari, M.; Beau, F.; Cuniasse, P.; Dive, V.; Yiotakis, A. Evaluation of PI’-Diversified Phosphinic Peptides Leads to the Development of Highly Selective Inhibitors of MMP-11. *J. Med. Chem. 2004*, 47, 325–336. [CrossRef]
189. Wang, J.; Radomski, M.W.; Medina, C.; Gilmer, J.F. MMP inhibition by barbiturate homodimers. *Bioorganic Med. Chem. Lett. 2013*, 23, 444–447. [CrossRef]
190. Tauro, M.; Laghezza, A.; Loidice, F.; Agamennone, M.; Campestrè, C.; Tortorella, P. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. *Bioorganic Med. Chem. 2013*, 21, 6456–6465. [CrossRef]
191. Von Reedern, E.G.; Grams, F.; Brandstetter, H.; Moroder, L. Design and synthesis of malonic acid-based inhibitors of human neutrophil collagenase (MMP8). *J. Med. Chem. 1998*, 41, 339–345. [CrossRef] [PubMed]
192. Suojanen, J.; Salo, T.; Koivunen, E.; Sorsa, T.; Pirilä, E. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. *Cancer Biol. Ther. 2009*, 8, 2362–2370. [CrossRef] [PubMed]
193. Nuti, E.; Casalini, F.; Santamaria, S.; Gabelloni, P.; Bendinelli, S.; da Pozzo, E.; Costa, B.; Marinelli, L.; la Pietra, V.; Novellino, E.; et al. Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. *Eur. J. Med. Chem. 2011*, 46, 2617–2629. [CrossRef] [PubMed]
194. Erić, S.; Ke, S.; Barata, T.; Solmajer, T.; Stanković, J.A.; Juranić, Z.; Savić, V.; Zlož, M. Target fishing and docking studies of the novel derivatives of ary1-aminopyridines with potential anticancer activity. *Bioorganic Med. Chem. 2012*, 20, 5220–5228. [CrossRef] [PubMed]
195. Fainaru, O.; Pencovich, N.; Hantisteanu, S.; Yona, G.; Hallak, M. Immature myeloid cells derived from mouse placentas and malignant tumors demonstrate similar proangiogenic transcriptional signatures. *Fertil. Steril.* **2013**, *99*, 910–917. [CrossRef] [PubMed]

196. Hu, J.; Yan, M.; Pu, C.; Wang, J.; van den Steen, P.E.; Opdenakker, G.; Xu, H. Chemically synthesized matrix metalloproteinase and angiogenesis-inhibiting peptides as anticancer agents. *Anti-Cancer Agents Med. Chem.* **2014**, *14*, 483–494. [CrossRef]

197. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ* **2009**, *339*, b2535. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).